Categories
Report

CSSI PROFILE

Costas, Inc.          Standard Dental Labs

OUR NEW PROFILE IS:    (OTC: CSSI)

_______________

CSSI COMPLETES ACQUISITION OF FLORIDA BASED, PRIME DENTAL LAB, LLC

COSTAS REPORTS 2022 3RD QUARTER REVENUE AND EXIT FROM SHELL STATUS

THE ACQUISITION OF PRIME DENTAL DELIVERS MORE THAN TEN YEARS OF EXPERIENCE AND 2021 UNAUDITED GROSS REVENUE IN EXCESS OF $600,000.

______________________________

Hello Everyone,

The market just opened seconds ago and we have CSSI on our radar for today.  

This one is extremely thin and has a very limited history so make sure you are watching it very close this morning.

It is a company that you want to get on you’re radar right now as things look like they are still in it’s infancy but progressing forward as you follow the press releases below.

May be an image of text that says 'SDL'

CSSI has developed branding and a detailed business plan to facilitate the acquisition of small to medium sized dental labs, of which there are thousands in the United States. Similar models have been extensively used in the medical clinic and dental clinic industries over the past 30 years, but dental laboratories remain highly fragmented. “Consolidating small, privately owned labs into larger, regionally managed facilities will bring economies of scale, and enhance competitiveness and product quality in regional markets.” said Costas CEO, James Brooks. 

SDL has been actively looking for dental lab owners interested in selling their labs over the recent months. With the recently acquired consolidation model and ready to launch branding, the Company expects to identify several suitable acquisition targets in the coming weeks and months, with the goal of becoming one of the largest operators in the industry. “There’s no faster way to grow than through acquisition, and this industry, in particular, remains unsophisticated in the public sector.”, added Brooks.

Consolidation of this industry, currently represented by 7,000+ privately owned businesses, is now the Company’s focus. The acquired business model will allow the Company to quickly identify suitable targets, to build and scale in order to become regionally competitive. In the process, the Company will be positioning itself as a leader in setting new standards for the dental lab industry.

Acquiring cash flowing, and profitable businesses with a financial track record, is Standard Dental Labs business strategy. The dental lab industry as a whole is estimated to be a $10B market in the US alone in 2022 (source: Grandview Research, Aug. 2021), but is growing steadily.

As you read the press releases below you will see the progression of the business plan start to unfold from the acquisition of a company, to their first revenue generating acquisition to removal of shell status and a planned uplisting to a higher quality exchange.

COSTAS, INC. CLOSES AGREEMENT TO ACQUIRE ASSETS OF STANDARD DENTAL LABS INC

ORLANDO, FL / ACCESSWIRE / May 6, 2022 / Costas, Inc. (OTCMKTS:CSSI), Costas, Inc. (“CSSI” or “the Company”). About COSTAS (CSSI): 

COSTAS, INC. is a publicly traded company listed on OTCMarkets under the trading symbol ‘CSSI’. As previously announced, on February 28th, 2022, the shareholders of Standard Dental Labs Inc. (“SDL”) voted unanimously in favor of accepting an offer from CSSI to acquire its assets. The Company is pleased to announce the parties have entered into a formal acquisition agreement, which is expected to close in the coming days. The completion of this acquisition will cement the Company’s entry into the dental lab industry, paving the way for future acquisitions and consolidations in the industry.

The business model acquired from SDL, a company incorporated in Wyoming in 2019, and controlled by Mr. Brooks, the Company’s CEO, has developed branding and a detailed business plan to facilitate the acquisition of small to medium sized dental labs, of which there are thousands in the United States. Similar models have been extensively used in the medical clinic and dental clinic industries over the past 30 years, but dental laboratories remain highly fragmented. “Consolidating small, privately owned labs into larger, regionally managed facilities will bring economies of scale, and enhance competitiveness and product quality in regional markets.” said Costas CEO, James Brooks.

SDL has been actively looking for dental lab owners interested in selling their labs over the recent months. With the recently acquired consolidation model and ready to launch branding, the Company expects to identify several suitable acquisition targets in the coming weeks and months, with the goal of becoming one of the largest operators in the industry. “There’s no faster way to grow than through acquisition, and this industry, in particular, remains unsophisticated in the public sector.”, added Brooks.

COSTAS, INC. COMPLETES ACQUISITION OF FLORIDA BASED DENTAL LAB, PRIME DENTAL LAB, LLC

ORLANDO, FL / ACCESSWIRE / August 16, 2022 / Costas, Inc. (OTC PINK:CSSI), Costas, Inc. (“CSSI” or “the Company”). About COSTAS (CSSI):

COSTAS, INC. is a publicly traded company listed on OTCMarkets under the trading symbol ‘CSSI’. The Board of Directors of CSSI is pleased to announce the completion of a definitive agreement to acquire Prime Dental Lab, LLC. (“Prime Dental”), an Orlando-based dental lab in operation since 2012, under the ownership and management of Mr. John Kim. The acquisition of Prime Dental delivers more than ten years of experience and 2021 unaudited gross revenue in excess of $600,000.

The opportunity to acquire Prime Dental follows the May 6, 2022, acquisition of certain assets of Standard Dental Labs Inc. (“SDL”), a company founded by CSSI CEO, James Brooks. Now operating under the DBA SDL, CSSI is currently searching for dental lab owners that have struggled to find an exit from the industry, intending to retire or who lack the resources to remain competitive. Among the assets acquired from SDL was the comprehensive business plan and roll up strategy aimed to facilitate the acquisition of these small to medium-sized dental labs, of which there are thousands in the United States. 

On August 15, 2022, following a due diligence process, CSSI and Prime Dental executed an Asset Purchase Agreement. Total consideration of $700,000.00 will be paid to the shareholders of Prime Dental in a combination of cash and registered shares for the assets, which includes all equipment, the client base, and associated revenue. Shares will be escrowed over two years, paid in quarterly installments. Although both parties have executed the agreement, it will not be ratified until the submission of a Form S-1 Registration with the Securities and Exchange Commission and receipt of notice of effect.

The acquisition of Prime Dental is the latest in a series of dental labs the Company plans to acquire in the coming years. CSSI’s mandate is to acquire cash-flowing, profitable businesses with strong financial track records and consolidate these operations, achieving operational efficiencies and enhancing the bottom line. Prime Dental brings immediate revenue-generating operations, and CSSI plans to facilitate access to previously inaccessible cutting-edge equipment, kickstarting growth.

In 2022, the dental lab industry is estimated to be a $10B market in the US (source: Grandview Research, Aug. 2021) and continues to grow. Therefore, consolidation within the industry, represented by 7,000+ privately owned businesses, is the Company’s focus. In the process, Costas Inc. will be positioning itself as a leader in setting new standards for the dental lab industry. It expects to continue identifying suitable acquisitions in the coming weeks and months, focusing on becoming one of the largest operators in the industry.

COSTAS REPORTS 2022 3RD QUARTER REVENUE AND EXIT FROM SHELL STATUS

ORLANDO, FL / ACCESSWIRE / November 30, 2022 / Costas, Inc. (OTC PINK:CSSI) (“CSSI” or “the Company”), doing business as Standard Dental Labs Inc., reports that it has recorded 3rd quarter gross revenues of $44,770 in its most recent quarterly financial report. The third quarter revenues are the result of the recent acquisition of operating assets, including customer contracts and lab equipment, from Prime Dental Labs with an effective date of September 1, 2022. The reported revenues are the Company’s first recorded revenues under new management from planned dental lab acquisitions and operations.

Now that Standard Dental Labs expects to report ongoing monthly revenue, the Company has also filed a supplemental notice to shareholders notifying them that the Company is no longer a “Shell Company”, as defined under Rule 405 of the US Securities Act of 1933 (“Rule 405”). The removal of the “Shell” symbol on the OTCMarkets landing page, once removed by OTCMarkets, will be a significant milestone for Costas, Inc., and evidence of the Company’s continuing effort to improve corporate governance and disclosure compliance for shareholders. The determination to remove Shell status is at the sole discretion of OTCMarkets, and is not an indicator of any compliance issues.

The Company will continue to make efforts to acquire more dental labs in the Orlando, Florida region, with the goal of consolidating those labs into one, larger location where we will be able to capitalize on the economies of scale and joint experience.

In 2022, the dental lab industry is estimated to be a $10B market in the US (source: Grand View Research, Aug. 2021) and continues to grow. Therefore, consolidation within the industry, represented by 7,000+ privately owned businesses, is the Company’s focus. In the process, the Company will be positioning itself as a leader in setting new standards for the dental lab industry. It expects to continue identifying suitable acquisitions in the coming weeks and months, focusing on becoming one of the largest operators in the industry.

COSTAS, INC. ENGAGES INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM, PROGRESSING CORPORATE ROADMAP

ORLANDO, FL / ACCESSWIRE / August 24, 2022 / Costas, Inc. (OTC PINK:CSSI), Costas, Inc. (“CSSI” or “the Company”). About COSTAS (CSSI):

COSTAS, INC. is a publicly traded company listed on OTCMarkets under the trading symbol ‘CSSI’. The Company is pleased to report that it has recently engaged an Independent Registered Public Accounting Firm to audit the financial results for Costas, Inc. (OTCMKTS: CSSI) and Prime Dental Lab LLC. for the most recent two fiscal years ended December 31, 2021 and 2020, and the six-month comparative interim periods ended June 30, 2022 and 2021. As previously announced, on August 15, 2022, Costas entered into an agreement to purchase the assets of Prime Dental Lab LLC, including its client base and revenue (the “Asset Purchase Agreement”).

The Independent PCAOB Registered Public Accounting Firm will audit both companies according to US GAAP; including a review of revenue recognition policies in accordance with ASC 606.

The objective for Costas is to become a fully reporting issuer with a class of securities registered with the Securities and Exchange Commission (“SEC”), while substantially growing revenue generating operations via the acquisition of central labs with existing manufacturing capabilities. The Company expects to complete the audits and file a Form S-1 Registration with the SEC. Within the next few months, CSSI hopes to be listed on the OTCQB and maintain business as a fully reporting issuer.

NEWS

Costas Reports 2022 3rd Quarter Revenue and Exit from Shell StatusPRESS RELEASE | 11/30/2022

Costas, Inc. Engages Independent Registered Public Accounting Firm, Progressing Corporate RoadmapPRESS RELEASE | 08/24/2022

Costas, Inc. Completes Acquisition of Florida Based Dental Lab, Prime Dental Lab, LLCPRESS RELEASE | 08/16/2022

Costas, Inc. Closes Agreement To Acquire Assets of Standard Dental Labs Inc.PRESS RELEASE | 05/06/2022

Costas, Inc. Makes Offer to Purchase Standard Dental Labs Inc.PRESS RELEASE | 03/02/2022

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY TWO THOUSAND USD BY A THIRD PARTY, AWARENESS CONSULTING NETWORK LLC  FOR A ONE DAY CSSI AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS, LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

CTXR PROFILE

OUR NEW PROFILE IS:    NASDAQ: CTXR 

“MINO-WRAP” COULD REVOLUTIONIZE $400 MILLION POST-MASTECTOMY INFECTION PREVENTION MARKET

$41.7 MILLION IN CASH AND CASH EQUIVALENTS AS OF SEPTEMBER 30, 2022

MINO-LOK® PHASE 3 TRIAL CLOSER TO COMPLETION WITH 169 PATIENTS RECRUITED, 72 FAILURE EVENTS AND 17 PATIENTS IN ACTIVE TREATMENT OR PENDING DATA REVIEW

DOWNLOAD THE INVESTOR PRESENTATION HERE

DOWNLOADS THE FACT SHEET HERE

_______________________________

Hello Everyone,

We have another exciting profile for Monday’s session.

Pull up CTXR Immediately.

Citius Pharmaceuticals, Inc. (Citius) is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a diversified pipeline of five active programs. Three of its pipeline candidates would be the first and only prescription treatments in their indications if approved by the FDA. The Company has two late-stage product candidates, Mino- Lok®, an antibiotic lock solution to salvage infected central venous catheters (CVCs) of patients with catheter-related bloodstream infections (CRBSIs), which is currently enrolling patients in a Phase 3 Pivotal superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma (CTCL), which has completed its Phase 3 trial and is on track for submission of a biologics license application (BLA) with the U.S. Food and Drug Administration (FDA) in the second half of 2022. Mino-Lok® was granted Fast Track designation by the FDA. I/ONTAK has received orphan drug designation by the FDA for the treatment of CTCL and peripheral T-cell lymphoma (PTCL). Citius has announced its intention to spinoff I/ONTAK into standalone oncology-focused publicly traded company. During the second quarter of 2022, Citius initiated a Phase 2b trial of Halo-Lido, potentially the first and only FDA-approved prescription treatment for hemorrhoids; patient enrollment in the trial is expected to be completed by the end of 2022. Citius has two additional pipeline assets in pre-clinical devleopment: a novel proprietary mesenchymal stem cell (i-MSC) treatment for acute respiratory conditions, and Mino-Wrap, for the prevention of infection in tissue expanders and breast implants post mastectomy.

There are several catalysts in play right now that we need to look at:

ANALYST TARGET:

Dawson James Analyst Jason Kolberts’ $10.00 target could mean potential upside of 1,198% for Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) right after bouncing off its 52-week low of $.77 cents on 12/30/22 according to Barchart.com’s price history.(32)(33)

ACTIVE CHART:

Since bottoming out and hitting its 52-week low of $.77 cents on 12/30/22, shares of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) have climbed to $1.13 for a solid 46.75% move in less than 10 days.(33)

FDA CONFIRMATION:

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) has reported that the FDA confirmed Prescription Drug User Fee Act (PDUFA) target action date of July 28, 2023.(35)

PHASE 3 TRIAL:

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) completed Pivotal Phase 3 trial of I/ONTAK (E7777) and submitted biologics license application (BLA) to the U.S. Food and Drug Administration (FDA).(35)

BIOTECH CLUSTER WITH 70 NEW FDA APPROVALS:

The company is headquartered in a hotbed and breeding ground for successful Biotechs, which were responsible for a staggering 70 new FDA dr-ug approvals between 2020 and 2021.(40)

ACCELERATED ADVANCEMENT:

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) expanded and accelerated its Phase 3 Mino-Lok trial to additional sites outside the United States. If approved, Mino-Lok would be the first-and-only antibiotic lock solution FDA-approved to salvage infected central venous catheters (CVCs) causing catheter-related bloodstream infections (CRBSIs).(35)

CLINICAL COLLABORATION:

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) initiated a clinical collaboration with the University of Pittsburgh to evaluate regulatory T-cell (T-reg) depletion with I/ONTAK (E7777) in combination with pembrolizumab in recurrent or metastatic solid cancer tumors in a Phase 1 investigator-initiated trial, with first patient enrolled in November 2022.(37)

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) Gets $10.00 Target From Dawson James Analyst Jason Kolberts.

Jason Kolberts is no stranger to the biotech and pharmaceutical industries.

He’s actually the Director of Research at Dawson James Securities, Inc.

And for those who don’t know, Dawson James is a full-service boutique investment banking firm focused on emerging growth companies since 2004 and committed to helping clients navigate the healthcare, biotechnology and technology markets. (38)

Jason Kolberts’ career began as a chemist in the pharmaceutical industry and evolved into a product and marketing manager with Schering-Plough in Japan. Upon returning from Japan, Jason joined Salomon Smith Barney, as a research associate which has now evolved into a 20-year career on Wall Street as a leader in the Healthcare space.(38)

Kolberts’ coverage expands across multiple therapeutic areas in biotechnology, specialty pharmaceuticals, and medical devices. As an analyst Jason has developed a high level of expertise in oncology, virology and cell-based medicine such as CAR (Chimeric Antigen Receptor)-T cells and regenerative medicine (stem cells).(38)

Prior to joining Dawson James, Mr. Kolbert spent the prior year as a senior biotechnology analyst at HC Wainwright and spent the previous seven years at the Maxim group, where he was an Executive Managing Director and the Head of Healthcare Research at the firm. During this period Jason and his team covered 80 names across the healthcare vertical. Jason’s Wall Street career began with seven years at Citi Group followed by several years on the buy side as a portfolio manager with the Susquehanna International Group.(38)

One company that seems to have caught the eye of Jason Kolbert is Citius Pharmaceuticals, Inc. (Nasdaq: CTXR).

Mr. Kolbert has a $10.00 target on Citius Pharmaceuticals, Inc. (Nasdaq: CTXR).(32)

This could mean a potential upside of 1,198% for Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) after a recent bounce off its 52-week low of $.77 cents on 12/30/22 according to Barchart.com’s price history.(33)

Listen. Nothing is certain. But look at the Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) weekly chart above and do a little technical analysis using StockCharts.com. You can see the following moving averages:(39)

Weekly average price is: $1.12 (as of 1/13/23)

50-day moving average at $1.18

200-day moving average at $1.28

20-day exponential moving average $1.07 (first line of resistance)

Shares of (CTXR) just trended above its first line of potential resistance at the $1.07 – $1.12 range(39). If (CTXR) is able to push through its 50-day moving average of $1.18… the next line of potential resistance could be its 200-day moving average at $1.28, which, if reached, would represent a potential 28% move as of 1/13/23’s opening price of $1.00.(38)(33) A move back to the 200-day moving average is not certain, but the potential should be noted.

How would that move be possible?

You see, shares of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) could be at the beginning of what’s called a “Descending Triangle Breakout Strategy.”(39)

…And by definition, the “Descending Triangle Breakout Strategy” as the name suggests, involves the anticipation of a breakout from the descending triangle pattern. (41)

The basic premise of using this strategy is to look at volume once you’ve identified the pattern. You can typically observe that volume begins to diminish toward the end of the descending triangle pattern formation. (41)

After bottoming out and hitting its 52-week low of $.77 cents on 12/30/22, shares of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) have climbed to $1.13 for a solid 46.75% move in less than 10 days.(33)

Could this be the beginning of a much larger move?

Shares of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) would need to climb over 1,198% to reach the $10.00 target set by Dawson James Analyst, Jason Kolberts, from that 52-week low.(32)

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) Has Built a Diversified Pipeline of Therapeutics with a Multi-Billion-Dollar Total Addressable Market.(43)

Non-Hodgkin’s Lymphoma is one of the deadliest forms of cancer. 

Targeting your body’s germ-fighting immune system, it invades your body’s lymph nodes. Left unchecked, it can kill more than 1-in-3 of those diagnosed, with over a half-million new cases each year.

But one company could be set to change all that…

Flying well under the radar, Citius Pharmaceuticals (NSDQ: CTXR) has quietly acquired the rights to the experimental compound “E-7777,” (27)a direct improvement to a previously FDA-approved medication that directly attacks infected cancer cells inside the human body.

And this new cancer-fighting remedy could be mere months away from its own approval. If and when it hits the market, this new treatment could provide a whole new proven alternative to the harsh side effects of chemotherapy or aggressive radiation treatment.

Directly targeting and attacking infected cells, E-7777 could transform the $5.4 Billion market for Non-Hodgkin’s Lymphoma treatment.

The best part of this whole story? This is just one of several potentially game-changing new therapies in the company’s pipeline …

CITIUS PHARMACEUTICALS, INC. IS A BIOPHARMA POWERHOUSE HIDING IN PLAIN SIGHT

Citius Pharmaceuticals United States NASDAQ: (CTXR) is what’s called a “late-stage biopharmaceutical” company, where a highly-experienced management team purchases rights to the most promising new therapies and then either brings them to market or licenses rights to bigger pharma companies like Pfizer or Johnson & Johnson.

It should go without saying that “late-stage” development is the most difficult, most expensive part of the process for any new kind of treatment. Because even after years of investment, research and development, some 2 out of 5 drugs still fail to secure final FDA approval.(30)

But with a “Dream Team” of top industry insiders, Citius is turning the odds in their favor—with two treatments now in Phase 3, and both looking like they will pass.

In addition to E-7777, it’s currently advancing three proprietary product candidates in total:(12)

• Mino-Lok has advanced to Phase 3 clinical studies.
• CITI-101 (Mino-Wrap) is a malleable, bio-absorbable film impregnated with minocycline and rifampin. It is designed to reduce infections associated with the use of breast tissue expanders (TE) used in breast reconstruction surgeries following mastectomies.
• CITI-002 is being developed to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids.

We’re going to focus primarily on Mino-Lok here, since it’s Citius Pharmaceuticals’ most promising (and most immediate) potential revenue source …

Source 13

MINO-LOK’S PHASE 3 CLEARANCE COULD BE THE KEY TO COMMANDING A $1.5 BILLION 2 MARKET:

Mino-Lok is an antibiotic designed to treat patients with catheter-related bloodstream infections (CRBSIs). At present, these infections are treated by removing the catheter and prescribing antibiotics.

This is a costly medical process with potential complications. In fact, studies show that removal and reinsertion of CVCs have a 15% to 20% complication rate, including pneumothorax, misplacement, and arterial puncture. (4)

Mino-Lok allows doctors to treat the infection without needing to remove the catheter, avoiding both costs and complications.

North America is projected to account for a major share of the global catheter-related bloodstream infections market during the forecast period due to well-established health care infrastructure. Europe is anticipated to be the second largest market from 2020 to 2030. (31)

This market has very little, if any, competition

But here’s the biggest catalyst for Citrus, the global catheter-related bloodstream infections market is highly consolidated due to the presence of a small number of key players – which means at this time there is very little in the way of competition. (31)

Currently, in Phase 3 pivotal trials, it could be approved in a matter of months … giving Citrus a massive leg up on any competition.

According to CEO Myron Holubiak: (14)

“Data from the Mino-Lok® (M-L) Phase 3 program was reviewed by our independent Data Monitoring Committee (DMC) for safety and efficacy and found to be progressing as planned with no recommended changes to trial design.”

MINO-LOK HAS REPORTEDLY PERFORMED WELL TO DATE: (18)

• Mino-Lok is the first and only therapy under investigation to salvage infected CVCs. In a Phase 2b trial, the Mino-Lok product demonstrated a 100% efficacy rate in salvaging colonized CVCs.
• Mino-Lok had no significant adverse events compared to an 18% serious adverse event rate when infected CVCs were removed and replaced.
• FDA Fast Track with QIDP designation and patent protection until June 2024. Formulation patent protection until November 2036. Currently in a Phase 3 pivotal superiority trial. (14)

MEANWHILE, CITIUS’ “MINO-WRAP” COULD REVOLUTIONIZE $400 MILLION
POST-MASTECTOMY INFECTION PREVENTION MARKET

Citius’ Mino-Wrap could help reduce post-operative infections associated with surgical implants. Its gel-containing film is used primarily to wrap the tissue expander used in breast reconstructive surgeries.

As also noted by CEO Holubiak: (14)

“We believe that this serious condition impacts about 100,000 women in the U.S. and many more in the rest of the world. Mino-Wrap is a bio-absorbable, antimicrobial semi-solid film that is wrapped around a tissue expander and placed in the surgical pocket following a mastectomy to prevent post-surgical infections. Once implanted, Mino-Wrap slowly dissolves in situ for a specified period of time, providing extended protection against infection.”

PROGRAM HIGHLIGHTS (19)

• Potential to be first and only FDA-approved product to prevent infections associated with post-mastectomy breast implants
• Currently in preclinical development
• Development in partnership with The University of Texas MD Anderson Cancer Center and support from medical thought leaders

Get Instant Access to Investor Materials 

OFFERING RELIEF IN AN $80 MILLION HEMORRHOIDS MARKET

Shockingly, there are no FDA-approved prescription products for hemorrhoids at the moment.(16)

However, that could soon change with Citius’ halobetasol and lidocaine formulations.

Hemorrhoids are an uncomfortable and often recurring condition. However, despite the numerous prescriptions and over the counter (OTC) products commonly used to treat hemorrhoids, none possess the necessary safety and efficacy data generated from rigorously conducted clinical trials.

Citius believes its halobetasol-lidocaine product could one day become that go-to treatment for physicians wanting to provide patients with a therapy demonstrating safety and efficacy.(16)

PROGRAM HIGHLIGHTS: (20)

• There are no FDA-approved prescription products on the market for hemorrhoids
• Citius’ halobetasol and lidocaine formulation could become the first FDA-approved prescription product to treat hemorrhoids in the United States
• According to IMS, over 25 million units of topical combination prescription products for hemorrhoids are sold in the US

CITIUS PHARMACEUTICALS COULD EVEN HELP TREAT ARDS, TOO

• There are about three million cases of Acute Respiratory Distress Syndrome (ARDS) globally, with approximately 200,000 instances just in the U.S.(17)
• The health crisis significantly added to the amount of ARDS cases, with death rates among patients on ventilators as high as 50%.(17)

• Worse, at the moment, there are no approved treatments for ARDS.(17)

According to Citius CEO Holubiak:

“Currently, there is no FDA-approved drug therapy for ARDS. We plan to submit an IND to the FDA and initiate our Phase 1 study by the end of the second quarter of 2022. Our first-in-human clinical trial is entitled “i-MSCs in Subjects with Acute Respiratory Distress Syndrome (ARDS) Due to [the health predicament]: i-MARCO.” Following the completion of a multi-center Phase 1 pilot study, we would expect to proceed on to a double-blinded, randomized Phase 2/3 trial to demonstrate the safety, efficacy, and multimodal healing capabilities of our i-MSCs in patients with moderate to severe ARDS due to [the health predicament].” (14)

PROGRAM HIGHLIGHTS: (21)

• Novel stem cell therapy for the treatment of acute inflammatory respiratory disorders including acute respiratory distress syndrome (ARDS)
• i-MSCs derived from induced pluripotent stem cell reprogrammed using proprietary mRNA process
• No FDA-approved treatment for ARDS exists today
• Preclinical activities are underway

Get Instant Access to Investor Materials 

$7.2 BILLION IN POTENTIAL MARKET DISRUPTION

As you’ve seen today, some of the treatments in Citius Pharmaceuticals’ portfolio go far beyond the definition of “Cutting Edge” …

Mino-Lock could potentially erase the need to operate on those suffering from Catheter-Related Bloodstream Infections (CRBIs), revolutionizing treatment of a $1.5 Billion medical problem overnight. E-7777 could offer a powerful new alternative to those suffering from Non-Hodgkin’s Lymphoma.

Combined with a full pipeline of other treatments, Citius Pharmaceuticals could be sitting on top of $5.5 Billion in cumulative pharmaceutical market disruption…

With a full year’s “cash runway” (through December 2023)(43)left to complete critical Research & Development, along with the outrageous profit potential if even one of these treatments makes it to market, Citius Pharmaceuticals (NSDQ:CTXR) is a company that should definitely be on your radar.

CITIUS PHARMACEUTICALS, INC. (NASDAQ: CTXR) IS HEADQUARTERED IN ONE OF THE COUNTRY’S HOTTEST BREEDING GROUNDS FOR FOR SUCCESSFUL BIOTECH’S

“This was the first year that Citius qualified for the program, and we are delighted to have been selected to participate in New Jersey’s NOL Program. As a pre-revenue business, this program allows us to convert certain losses from operations into tangible working capital today, supporting our ongoing research and development efforts. We are thankful to the NJ Economic Development Authority for aiding our efforts in our initial year of participation. This non-dilutive funding will provide added cash runway as we advance a late-Phase 3 trial for Mino-Lok®, a Phase 2b trial for Halo-Lido, and a recently submitted biologics license application (BLA) for I/ONTAK,” stated Jaime Bartushak, Chief Financial Officer of Citius.(45)

New Jersey’s biotechnology cluster has grown from a mere 30 companies in the early 1990s to approximately 3,200 establishments in the state today. 46 of those firms are responsible for a staggering 70 new FDA drug approvals between 2020 and 2021, according to the trade association BioNJ.(40)

And several sources indicate that despite recent IPO and capital market challenges, the biotech cluster’s ascension continues.(40)

Debbie Hart, president and CEO of BioNJ, says of the overall US/global biotech community: “The science is advancing by leaps and bounds, and it’s creating lots of opportunities, new companies, and new advances in therapies and treatments.”(40)

“When you look at what happened during the global pandemic – how the industry can really save the world – [it’s] not an understatement. It just speaks to ability and the science.”(40) 

New Jersey’s specific biotech juggernaut partly stems from a constellation of cutting-edge advances in cell and gene therapy operating in tandem with a Garden State life sciences ecosystem replete with contract manufacturing and clinical research organizations, as well as specialized accountants, attorneys, and other professionals who serve the industry.(40)

Such a network is particularly important for the biotechnology community given the challenges it faces.(40)

Dean J. Paranicas, president and CEO of the HealthCare Institute of New Jersey (HINJ), details the overall “high-risk profile” for the biopharmaceutical industry: “There’s that challenge of having enough capital to develop your product, being able to get it through the regulatory cycle, and then commercializing [it] and getting it into the marketplace.”(40)

Paranicas additionally explains that New Jersey firms have beneficial opportunities to coordinate with the state’s research institutions as well as with more established companies located here.(40)

Also helping to lubricate the state’s growing industry is New Jersey’s proximity to Wall Street and, separately, a time-zone advantage, which facilitates business communication with locales as diverse as, say, California and the United Kingdom.(40)

In November of 2022, Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced it had secured $3.6 million through New Jersey Economic Development Program.(45)

CITIUS PHARMACEUTICALS, INC. (NASDAQ: CTXR) ANNOUNCES A CLINICAL COLLABORATION WITH THE UNIVERSITY OF PITTSBURGH.(46)

Source 47

The study consists of two parts. Part I is a dose escalation study of four cohorts (3,6,9,12 mcg of I/ONTAK) and is expected to enroll 18-30 patients. Part II is a dose expansion study of approximately 40 patients to evaluate the safety and tolerability of the recommended combination dose of I/ONTAK and pembrolizumab.(46)

The study will also investigate the alteration of the immune microenvironment within tumors and peripheral blood. Secondary endpoints include the objective response (complete response plus partial response), progression-free survival, and overall survival.

I/ONTAK is a recombinant fusion protein that combines the interleukin-2 (IL-2) receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. I/ONTAK, a purified version of denileukin diftitox, is a reformulation of previously FDA-approved oncology treatment ONTAK.

ONTAK was marketed in the U.S. from 1999 to 2014, when it was voluntarily withdrawn from the market. Manufacturing improvements resulted in a new formulation, which maintains the same amino acid sequence but features improved purity and bioactivity. The new formulation received regulatory approval in Japan in 2021 for the treatment of CTCL and PTCL. In 2011 and 2013, the FDA granted orphan drug designation (ODD) to I/ONTAK for the treatment of PTCL and CTCL, respectively.(46)

Source 48

In September of 2022, Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced a collaboration with Dr. Haider Mahdi at the University of Pittsburgh in an investigator-initiated trial to evaluate I/ONTAK (“denileukin diftitox” or “E7777”) in combination with pembrolizumab in the treatment of recurrent or metastatic solid tumors.

“We are honored to support Dr. Mahdi and his team at the University of Pittsburgh in this Phase 1 investigator-initiated study to evaluate I/ONTAK as a combination therapy in the treatment of solid tumors. This study will expand the body of knowledge about I/ONTAK’s unique mechanism-of-action targeting the CD25 component of the IL-2 receptor which is present on both malignant T-cells (T-cell leukemias and lymphomas) and immunosuppressive regulatory T-cells (T-regs),” stated Dr. Myron Czuczman, Chief Medical Officer of Citius.

“Preclinical research in a syngeneic solid tumor mouse model shows that E7777 (denileukin diftitox) enhances anti-tumor activity and significantly extends survival benefit of anti-PD-1 therapy. This data provides a positive signal of denileukin diftitox’s potential in the immuno-oncology space. There remains a significant ongoing need for innovative, effective, and well-tolerated treatments for cancer patients with solid tumors, and we are excited that I/ONTAK may provide meaningful antitumor activity in combination with the PD-1 inhibitor pembrolizumab (KEYTRUDA®),” added Dr. Czuczman.(46)

Additionally, Citius is collaborating with an investigator-initiated study at the University of Minnesota (UMN). This Phase 1 dose-finding study to evaluate I/ONTAK prior to tisagenleucel (KYMRIAH®) CAR-T therapy in patients with diffuse large B-cell lymphoma (DLBCL) enrolled its first patient in May 2021.

The investigator-initiated trial at UPMC is an open label, Phase I/Ib study to evaluate T-reg cell depletion with I/ONTAK (E7777) in combination with pembrolizumab in recurrent or metastatic solid tumors.

“Encouraging clinical data emerging in the field of tumor immunotherapy have demonstrated that therapies focused on enhancing T-cell responses against cancer result in a significant survival benefit in patients with advanced malignancies. Overexpression of PD-L1 on tumor cells has been reported to impede anti-tumor immunity, resulting in immune evasion. The interruption of the PD-1:PD-L1 pathway combined with diminishing the suppressive effect by T-regs may represent an attractive strategy for restoring tumor-specific T-cell immunity. This first in human I/ONTAK plus anti-PD-1 combination immunotherapy study is a significant step towards advancing a T-cell-based therapeutic approach to treating solid tumors,” stated Dr. Haider Mahdi, University of Pittsburgh, Assistant Professor, Department of Obstetrics, Gynecology & Reproductive Sciences. Education & Training.(46)

Additionally, Citius is collaborating with an investigator-initiated study at the University of Minnesota (UMN). This Phase 1 dose-finding study to evaluate I/ONTAK prior to tisagenleucel (KYMRIAH®) CAR-T therapy in patients with diffuse large B-cell lymphoma (DLBCL) enrolled its first patient in May 2021.

The investigator-initiated trial at UPMC is an open label, Phase I/Ib study to evaluate T-reg cell depletion with I/ONTAK (E7777) in combination with pembrolizumab in recurrent or metastatic solid tumors.

CITIUS PHARMACEUTICALS, INC. (NASDAQ: CTXR) REPORTS FISCAL FULL YEAR 2022 FINANCIAL RESULTS, PROVIDES BUSINESS UPDATE, ENDING THE YEAR WITH OVER $41 MILLION IN CASH.(35)

Source 49
  • $41.7 million in cash and cash equivalents as of September 30, 2022; extends runway through December 2023.
  • Mino-Lok® Phase 3 trial closer to completion with 169 patients recruited, 72 failure events and 17 patients in active treatment or pending data review.
  • I/ONTAK BLA accepted for filing by the FDA; updated PDUFA target action date is July 28, 2023.
  • Halo-Lido Phase 2b trial progressed; data readout expected 2H 2023.
  • Multiple value-driving catalysts anticipated in 2023, including a potential drug approval and two trial completions.

On December 22, 2022 Citius Pharmaceuticals, Inc. (Nasdaq: CTXR)reported business and financial results for the fiscal full year ended September 30, 2022.

Fiscal Full Year 2022 Business Highlights and Subsequent Developments Completed Pivotal Phase 3 trial of I/ONTAK (E7777) and submitted biologics license application (BLA) to the U.S. Food and Drug Administration (FDA).

FDA confirmed Prescription Drug User Fee Act (PDUFA) target action date of July 28, 2023.

Advanced Mino-Lok® Phase 3 trial.

Initiated Phase 2b trial of Halo-Lido for the treatment of hemorrhoids in April 2022; patient enrollment ongoing with data readout expected 2H 2023.

Initiated clinical collaboration with the University of Pittsburgh to evaluate regulatory T-cell (T-reg) depletion with I/ONTAK (E7777) in combination with pembrolizumab in recurrent or metastatic solid cancer tumors in a Phase 1 investigator-initiated trial, with first patient enrolled in November 2022.

Approved for $3.6 million in non-dilutive capital through the New Jersey Economic Development Program to support ongoing research and development efforts.

“In 2022, we focused on execution across our key development programs: I/ONTAK, Mino-Lok and Halo-Lido. These efforts, combined with a prudent use of funds, enabled us to meaningfully advance our pipeline. We believe we have sufficient runway through December 2023 to realize additional value-creating milestones, including a potential FDA approval and two anticipated trial completions in the coming calendar year,” stated Leonard Mazur, Chairman and CEO of Citius.(35)

“Our Phase 3 Mino-Lok trial is now significantly closer to completion. While we expected to achieve 92 catheter failure events with 144 patients by the end of 2022, the trial’s observed catheter failure event rate has proven to be lower than anticipated. Consequently, we must continue recruiting patients. By successfully re-engaging with our U.S. trial sites as they recovered from the impact of CVD, we were able to drive patient recruitment. We have now exceeded our targeted enrollment and have achieved 72 of the required catheter failure events, with additional patients under review. To augment our recruitment efforts and continue the positive momentum in enrollment, we expanded the Mino-Lok trial to include sites in India. Once all new trial sites are fully activated, we will have nearly doubled our clinical site footprint. With these additional sites helping to drive incremental enrollment, we anticipate that the 92-event threshold required to complete the trial is achievable in the coming months,” added Mazur.(35)

“During the year, we also completed a Phase 3 trial and submitted a BLA for I/ONTAK, an oncology asset we in-licensed just over a year ago. Upon further discussion with the FDA, the PDUFA target date has been set for July 28, 2023…

We remain committed to establishing a robust commercial infrastructure to support I/ONTAK’s successful product launch, if approved. In the second half of 2022, we also extended our support for a Phase 1 investigator-initiated study of I/ONTAK in combination with pembrolizumab (Keytruda®1) to treat patients with recurrent or metastatic solid tumors…

This study has begun recruiting patients and is the second investigator-initiated trial to explore I/ONTAK’s potential as a combination therapy in much larger immuno-oncology markets…

We continue to believe I/ONTAK’s value extends beyond a potential initial indication in persistent or recurrent cutaneous T-cell lymphoma. Earlier in the year, we announced our intention to spin off I/ONTAK. Given broader market conditions, we continue to evaluate opportunities to further unlock this asset’s value,” continued Mazur.(35)

“In addition to advancing our Phase 3 trials, we initiated a Phase 2b trial for Halo-Lido, our prescription strength topical formulation for hemorrhoids. The trial began enrolling patients with symptomatic Grade II or III hemorrhoids in the second quarter of 2022. Recent recruitment has accelerated and we expect complete trial data available in the second half of 2023,” added Mazur.

“As financial stewards, we continuously evaluate the optimal capital structure for the company. We believe our anticipated catalysts, along with a healthy cash position, provide us with several strategic and financial options with which to continue advancing our pipeline…

This may include the previously announced potential spinoff of I/ONTAK into a standalone oncology company, pending market conditions, and other standalone financing alternatives available to us. We are encouraged by the multiple value-driving catalysts anticipated in calendar 2023, including a potential drug approval and two trial completions, and look forward to extending our positive momentum in the months ahead,” concluded Mazur.(35)

NEWS

01/11/2023

Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023

12/22/2022

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Financial Results and Provides Business Update

12/01/2022

Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

11/21/2022

Citius Pharmaceuticals, Inc. Secures $3.6 million through New Jersey Economic Development Program

11/09/2022

Citius Pharmaceuticals Announces Efficacy and Safety Data for its I/ONTAK (E7777) Phase 3 Study for Treatment of Cutaneous T-Cell Lymphoma to be Presented at the 64th American Society of Hematology (ASH) Annual Meeting

10/18/2022

Citius Pharmaceuticals to Present at the ThinkEquity Conference on October 26, 2022

10/06/2022

Citius Pharmaceuticals to Present at Dawson James Securities Small Cap Growth Conference on October 12, 2022

09/28/2022

Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

09/22/2022

Citius Pharmaceuticals Announces a Clinical Collaboration with the University of Pittsburgh to Evaluate T-reg Cell Depletion with I/ONTAK (E7777) in Combination with Pembrolizumab in Recurrent or Metastatic Solid Cancer Tumors in a Phase 1 Investigator-Initiated Trial

09/15/2022

Citius Pharmaceuticals, Inc. and its CFO & CBO Jaime Bartushak Honored by Somerset Hills Learning Institute

09/08/2022

Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

09/07/2022

Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

08/11/2022

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2022 Financial Results and Provides Business Update

07/12/2022

Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK (denileukin diftitox) for the Treatment of Cutaneous T-Cell Lymphoma

05/25/2022

Citius Pharmaceuticals, Inc. Announces Intention to Spinoff Late-Stage Oncology Asset, I/ONTAK, into a New Standalone Publicly Traded Company

05/18/2022

Citius Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference on May 24, 2022

05/12/2022

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2022 Financial Results and Provides Business Update

05/06/2022

Citius Pharmaceuticals to Accelerate Phase 3 Mino-Lok Trial by Expanding Trial Sites Internationally

05/03/2022

Citius Pharmaceuticals, Inc. Provides Business Update, Highlights Upcoming Milestones

04/26/2022

Citius Pharmaceuticals Enrolls First Patient in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

04/14/2022

Citius Pharmaceuticals to Present at the NobleCon18 Investor Conference on April 20, 2022

04/13/2022

Citius Pharmaceuticals Announces Key Management Realignment to Support Commercialization of Two Late-Stage Product Candidates

MANAGEMENT

LEONARD MAZUREXECUTIVE CHAIRMAN, DIRECTOR

Portrait

Mr. Mazur is an accomplished entrepreneur and pharmaceutical industry executive with notable accomplishments in founding and building multiple healthcare companies, and creating value and returns for investors. Mr. Mazur was the Chairman of Leonard-Meron Biosciences, Inc. prior to its merger with Citius in March 2016. He is also the cofounder and Vice Chairman of Akrimax Pharmaceuticals, LLC, a privately held pharmaceutical company specializing in producing cardiovascular and general pharmaceutical products. Akrimax was founded in September 2008, and has successfully launched prescription drugs while acquiring drugs from major pharmaceutical companies. From 2005 to 2012, Mr. Mazur co-founded and served as the Chief Operating Officer of Triax Pharmaceuticals LLC, a specialty pharmaceutical company producing prescription dermatological drugs. Earlier, he was the founder and Chief Executive Officer of Genesis Pharmaceuticals, Inc., a dermatological products company that marketed its products through dermatologists’ offices and co-promoted products for major pharmaceutical companies. In 2003, Mr. Mazur successfully sold Genesis to Pierre Fabre, a leading pharmaceutical company. Mr. Mazur has extensive sales, marketing and business development experience from previous tenures at Medicis Pharmaceutical Corporation, ICN Pharmaceuticals, Inc., Knoll Pharma (a division of BASF), and Cooper Laboratories, Inc.

Mr. Mazur is a member of the Board of Trustees of Manor College, and is a recipient of the Ellis Island Medal of Honor. Mr. Mazur received both his BA and MBA from Temple University, and served in the U.S. Marine Corps Reserves.

MYRON HOLUBIAKPRESIDENT AND CHIEF EXECUTIVE OFFICER, DIRECTOR

Portrait

Mr. Holubiak has extensive experience in managing and leading both large and emerging pharmaceutical and life sciences companies. Mr. Holubiak was co-founder, director and CEO of Leonard-Meron Biosciences, Inc. prior to its merger with Citius in March 2016. From 1998 to 2001, Mr. Holubiak served as President of Roche Laboratories, Inc., a premier multinational research-based pharmaceutical company. As President of Roche, Mr. Holubiak helped transform Roche Labs into a leading antibiotic and biotechnology company. During his 19-year tenure at Roche Labs, Mr. Holubiak also held multiple sales and marketing roles. Prior to Roche, Mr. Holubiak founded Emron, Inc., a health economics and managed care consulting company, and helped establish the Academy of Managed Care Pharmacy (AMCP). From 2012 to 2016, Mr. Holubiak served as Chairman of the Board of Bioscrip, Inc., a national home infusion company. Since 2010, Mr. Holubiak has served as a member of the Board of Directors of Assembly Biosciences, Inc. and its predecessor, Ventrus Biosciences, Inc., and is a trustee of the Academy of Managed Care Pharmacy Foundation.

Mr. Holubiak received a BS in molecular biology and biophysics from the University of Pittsburgh. He received advanced business training from Harvard Business School and the University of London, as well as advanced training in health economics from the University of York’s Centre for Health Economics.

JAIME BARTUSHAKCHIEF FINANCIAL OFFICER

Portrait

Mr. Bartushak is an experienced finance and operations professional for early-stage pharmaceutical companies, and has over 20 years of corporate finance, business development, M&A, restructuring, capital formation, and strategic planning expertise. Mr. Bartushak is a founder of Leonard-Meron Biosciences, and, as CFO, was instrumental in obtaining initial investment capital for its start-up in 2014. Earlier, Mr. Bartushak helped lead the sale of PreCision Dermatology, Inc. to Valeant Pharmaceuticals International, Inc., and before that, he led the financial efforts for the successful sale of Triax Pharmaceuticals to PreCision Dermatology.

Mr. Bartushak holds a Master of Science and BS from the New Jersey Institute of Technology.

MYRON S. CZUCZMAN, MDCHIEF MEDICAL OFFICER AND EVP

Portrait

Dr. Czuczman is an experienced physician-scientist, academic oncologist, and pharma executive with decades of experience in strategic design, implementation, and oversight for the global development of novel therapeutics for hematologic malignancies. Dr. Czuczman joined Citius from Celgene where he was Vice President, Global Clinical Research and Development, Therapeutic Area Head of Lymphoma/CLL. In this role, Dr. Czuczman managed a global team of physicians and scientists responsible for cross-functional development of compounds from proof-of-principle to worldwide registration. Prior to his career in pharma, Dr. Czuczman practiced medicine for over two decades at Roswell Park Cancer Institute, an NCI-designated comprehensive cancer center in Buffalo, NY, where he served as chief of the Lymphoma/Myeloma Service and head of the Lymphoma Translational Research Laboratory. In addition to his extensive publications record, membership and leadership roles on national and international research organizations, and consulting and advisory to dozens of pharma companies, Dr. Czuczman also attained the positions of tenured Professor of Medicine at the State University of New York at Buffalo School of Medicine and Biomedical Sciences and Professor of Oncology at Roswell Park Comprehensive Cancer Center.

Dr. Czuczman received his medical degree from the Pennsylvania State University College of Medicine after graduating magna cum laude in biochemistry from the University of Pittsburgh. He completed his Internal Medicine residency training at Weill Cornell North Shore University/MSKCC Program, followed by Medical Oncology/Hematology fellowship training at Memorial Sloan-Kettering Cancer Center in New York City.

GARY F. TALARICOEVP, OPERATIONS

Portrait

Mr. Talarico has served as EVP, Operations since March 2016. Mr. Talarico has successfully built and led all commercial activities for a number of start-up companies. Most recently, he was a founder, partner and Executive Vice President of Leonard-Meron Biosciences, Inc.; he was instrumental in acquiring its lead product. Previously, Mr. Talarico served as Senior Vice President of Triax Pharmaceuticals, from its founding to the sale of its assets. Mr. Talarico was a founder and Executive Vice President of Sales and Marketing for Reliant Pharmaceuticals, LLC; Reliant was later sold to GlaxoSmithKline plc. Before Reliant, he was Executive Vice President of Business Development for Ventiv Health. His earlier experience included tenures as Vice President of Sales for Medicis Pharmaceutical Corporation at its start-up, and Director of Sales at ICN Pharmaceuticals, Inc. Mr. Talarico is a graduate of Lewis University.

JAY WADEKARSVP, BUSINESS STRATEGY

Portrait

Mr. Wadekar has been associated with Citius since its inception. Prior to Citius, he lead the clinical program at Ischemix, Inc., a company developing novel therapies for cardiovascular conditions. Mr. Wadekar has more than thirty years of experience in areas of finance, corporate strategy, sales and senior leadership in the healthcare field. Mr. Wadekar has held numerous executive level positions throughout his career in biotechnology and pharmaceutical industries including Chairman and CEO of Able Laboratories, Inc. Most recently he served as a strategic advisor to Camber Pharmaceuticals, Inc. where he was instrumental in building the executive team and establishing Camber’s Sales Operations systems.

ALAN LADER, PHDVP, CLINICAL OPERATIONS

Portrait

Dr. Lader has served as VP, Clinical Operations since March 2016. Dr. Lader has over 25 years of experience in medical research. Prior to joining Citius, Dr. Lader was the Director of Clinical Operations for Ischemix, Inc. Dr. Lader was an Instructor in Medicine at Harvard Medical School and Brigham and Women’s Hospital, where he taught Integrated Human Physiology, and was Principal Investigator for NIH-funded studies in mechanisms of lung cancer metastasis. Dr. Lader has authored over 20 publications in peer-reviewed journals, and has presented more than 20 abstracts at scientific meetings. He received his PhD from the University of South Carolina School of Medicine. He received an MS degree from Rensselaer Polytechnic Institute in Biomedical Engineering and a BS degree in Bioengineering from Syracuse University.

ILANIT ALLENVP, INVESTOR RELATIONS

Portrait

Ms. Allen has more than 20 years of experience in corporate communications, investor relations, strategy and investment banking. Since 2014, Ms. Allen has provided investor relations counsel to more than two dozen private and public life science companies. Previously, she advised executives across a broad spectrum of industries and growth stages, including technology startups and Fortune 500 financial institutions. Ilanit began her career as an investment banking analyst at SG Cowen with a focus on mergers and acquisitions. Ms. Allen holds an MBA from Harvard Business School, a Bachelor of Science degree in Finance from The Wharton School, and a Bachelor of Arts degree in International Relations from the University of Pennsylvania.

Sincerely,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY A THIRD PARTY, LEGENDS MEDIA LLC  FOR A ONE DAY CTXR AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS, LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

SOURCE LIST

Source 2: https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-highlight-its-phase-3-clinical-trial-product-mino-lok-at-benzinga-biotech-small-cap-conference-on-march-25-301253709.html

Source 3: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093967/

Source 4: https://www.citiuspharma.com/opportunity/crbsis/

Source 5: https://www.everydayhealth.com/things-your-doctor-wont-tell-about-hospital-infections/

Source 6: https://www.gurufocus.com/news/697235/citius-announces-united-states-patent-trademark-office-registered-the-companys-minolok-trademark

Source 7: https://www.citiuspharma.com/mino-lok/

Source 8: https://www.citiuspharma.com/wp-content/uploads/2021/02/CTXR_Shareholder_Letter_Feb2021.pdf

Source 9: https://www.citiuspharma.com/mino-wrap/

Source 10: https://stockcharts.com/h-sc/ui?s=ctxr

Source 11: https://www.barchart.com/stocks/quotes/CTXR/opinion

Source 12: https://www.citiuspharma.com

Source 13:https://d1io3yog0oux5.cloudfront.net/_335875ea4142d81b5406df99d97e4cdf/citiuspharma/db/249/1064/pdf/3.19.2021.WEB.Presentation_Final.pdf

Source 14: https://www.citiuspharma.com/wp-content/uploads/2021/02/CTXR_Shareholder_Letter_Feb2021.pdf

Source 15: https://www.citiuspharma.com/mino-wrap/

Source 16: https://www.citiuspharma.com/halo-lido/

Source 17: https://ir.citiuspharma.com/press-releases/detail/122/citius-pharmaceuticals-signs-an-exclusive-worldwide

Source 18: https://citiuspharma.com/pipeline/mino-lok/default.aspx

Source 19: https://citiuspharma.com/pipeline/mino-wrap/default.aspx

Source 20: https://www.citiuspharma.com/halo-lido/#:~:text=There%20are%20no%20FDA%2Dapproved,hemorrhoids%20in%20the%20United%20States

Source 21: https://citiuspharma.com/pipeline/stem-cell-platform/default.aspx

Source 22: https://www.cancer.net/cancer-types/lymphoma-non-hodgkin/statistics#:~:text=The%20overall%205%2Dyear%20survival,survival%20rate%20is%20around%2063%25.

Source 23: https://pubmed.ncbi.nlm.nih.gov/30895415/

Source 24: https://www.nuventra.com/resources/blog/why-do-clinical-trials-fail/#:~:text=This%20means%20that%20around%202,3%20fail%20to%20reach%20approval.

Source 25: https://www.google.com/search?rlz=1C1CHBF_enUS977US977&q=NASDAQ:+CTXR&stick=H4sIAAAAAAAAAONgecRowS3w8sc9YSn9SWtOXmPU5OIKzsgvd80rySypFJLmYoOyBKX4uXj10_UNDZOSzSxLDLIzeBax8vg5Brs4BlopOIdEBAEAzts1gUwAAAA&sa=X&ved=2ahUKEwi9i77gz8r0AhV1SzABHY-TBrkQsRV6BAg0EAM&biw=1536&bih=792&dpr=1.25

Source 26: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ctxr/citius-pharmaceuticals/news/we-think-citius-pharmaceuticals-nasdaqctxr-can-afford-to-dri-1

Source 27: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ctxr/citius-pharmaceuticals#intrinsic-value

Source 28: https://github.com/SimplyWallSt/Company-Analysis-Model/blob/master/MODEL.markdown#value

Source 29: https://finance.yahoo.com/quote/CTXR/history?p=CTXR

Source 30: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609997/

Source 31: https://www.biospace.com/article/catheter-related-bloodstream-infections-market-rise-in-prevalence-of-bloodstream-infection-is-projected-to-drive-the-global-market

Source 32 : https://dawsonjames.com/wp-content/uploads/2022/12/CTXR.12.23.22_-final1.pdf

Source 33 : https://www.barchart.com/stocks/quotes/CTXR/price-history/historical

Source 34 : https://finance.yahoo.com/news/citius-pharmaceuticals-inc-announces-u-123000919.html

Source 35 : https://finance.yahoo.com/news/citius-pharmaceuticals-inc-reports-fiscal-213000115.html

Source 36 : https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-accelerate-phase-3-mino-lok-trial-by-expanding-trial-sites-internationally-301541596.html

Source 37 : https://www.prnewswire.com/news-releases/citius-pharmaceuticals-announces-a-clinical-collaboration-with-the-university-of-pittsburgh-to-evaluate-t-reg-cell-depletion-with-iontak-e7777-in-combination-with-pembrolizumab-in-recurrent-or-metastatic-solid-cancer-tumors-in–301631592.html

Source 38 : https://dawsonjames.com/wp-content/uploads/2019/06/KolbertDORPRFinal.pdf

Source 39 : https://schrts.co/fUAydCuY

Source 40 : https://njbmagazine.com/monthly-articles/njs-burgeoning-biotech-industry/

Source 41 : https://www.thebalancemoney.com/triangle-chart-patterns-and-day-trading-strategies-4111224

Source 42 : https://mma.prnewswire.com/media/1593817/Citius_Logo.jpg?p=facebook

Source 43 : https://s28.q4cdn.com/169506891/files/doc_presentation/2022/12/Corporate-Overview-December-2022-FINAL.pdf

Source 44 : https://www.marketwatch.com/investing/stock/ctxr?mod=search_symbol

Source 45 : https://www.prnewswire.com/news-releases/citius-pharmaceuticals-inc-secures-3-6-million-through-new-jersey-economic-development-program-301683193.html

Source 46 : https://www.prnewswire.com/news-releases/citius-pharmaceuticals-announces-a-clinical-collaboration-with-the-university-of-pittsburgh-to-evaluate-t-reg-cell-depletion-with-iontak-e7777-in-combination-with-pembrolizumab-in-recurrent-or-metastatic-solid-cancer-tumors-in–301631592.html

Source 47 : https://www.pitt.edu/sites/default/files/styles/tier_one_hero/public/2021-07/mission-t1-cl-top-aerial.jpg?h=2c66ef4f&itok=YlGwAwOr

Source 48 : https://pbs.twimg.com/media/FmDiCOXXEAEcTfc?format=jpg&name=large

Source 49: https://www.adva.com/-/media/adva-main-site/about-us/investors/financial-results/financial-statements/financial-statements.jpg?rev=c7ba9b4d5faa4f73aecf63165df2b1a2

Source 50: https://citiuspharma.com/about/management-team/default.aspx

Categories
Report

NEW NASDAQ: VUZI Profile

OUR NEW PROFILE IS:   (NASDAQ: VUZI)

__________

3Q2022 REVENUE OF $3.4M ROSE 14% BOTH SEQUENTIALLY AND YOY

VUZIX IS A PIONEER IN WEARABLE COMPUTING, AUGMENTED REALITY, OPTICS AND DISPLAY ENGINES AND HAS BEEN DELIVERING SOLUTIONS TO CUSTOMERS FOR OVER 20 YEARS

VUZI IS SITTING WITH JUST OVER $90 MILLION IN CASH

VUZIX ULTRALITE DEBUTS ON CES 2023, AND WINS AN INNOVATION AWARD FOR ITS NOVEL LIGHTWEIGHT TECHNOLOGY, LONG BATTERY HOURS, AND EXPANSIVE SMARTPHONE ACCESSORY APPLICATIONS

CHECK OUT THE INVESTOR PRESENTATION HERE

data:text/html;https://www.youtube.com/embed/mwcSxa1Cik0?autoplay=1;base64,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
__________________________

Hello Everyone,

We have certainly started off the new year with a bang.  Our last one was a very rare OTC profile.  We don’t have a lot of those coming across our desk but this one moved over 15% in 4 sessions from the average trade on Monday.

The Nasdaq profile before that opened at $1.50 and hit $1.94 the very next session.

Today we want you to take a look at a Tech company that already has a massive following and a lot of notoriety in the media.

Pull up Nasdaq: VUZI Immediately.

This is a company that has been on a tare coming off of the CES, the worlds premiere electronics show.  They debuted their Ultralite AR Glasses.  Their have been a few positive articles from prominent publishers like the Wall Street Journal and Tech Times.  These are glasses that have ordinary-looking plastic frames with a tiny projector tucked in one stem and a tiny battery and Bluetooth radio in the other. It also has Vuzix’s waveguides which is a layer in the glasses that bends the projector’s light into your line of sight.

I know I laughed the first time I really heard of a Tesla.  The concept of an electric car sounded ridiculous and I didn’t think that anyone would really buy them. I also never thought that re-charging could never be made something that is practical and easy to do.  Now if you drive down a California highway it seems like every 7th or 8th car could be a Tesla.  They are everywhere.

I really don’t think it would be a far-fetched statement to say that some of the concepts that VUZI have rolled out and AR Glasses could be part of our everyday life in the near future.  There is a whole generation getting older that grew up with some of the advanced technology that we use today. They didn’t have to learn it as adults.  It was part of their upbringing.  This isn’t something that will be unique to AR.  I think it will impact all areas of technology.

The company itself has a lot going on.  Vuzix is a leading supplier of Smart Glasses and Augmented Reality (AR) technologies and products for the consumer and enterprise markets. They have offices in Rochester, NY, Oxford, UK, and Tokyo, Japan and were founded back in 1997.  The Company’s products include personal display and wearable computing devices that offer users a portable high-quality viewing experience, provide solutions for mobility, wearable displays and augmented reality. Vuzix holds 274 patents and patents pending and numerous IP licenses in the Video Eyewear field. Moviynt, an SAP Certified ERP SaaS logistics solution provider, is a Vuzix wholly owned subsidiary. The Company has won Consumer Electronics Show (or CES) awards for innovation for the years 2005 to 2023 and several wireless technology innovation awards among others.

Their AR wearable display devices are worn like eyeglasses or attach to a head worn mount. These devices typically include a wearable computer, cameras, and sensors that enable the user to view, record and interact with video and digital content, such as computer data, the Internet, enterprise data, social media or entertainment applications. Their wearable display products integrate micro-display technology with our advanced optics to produce compact high-resolution display engines, less than half an inch diagonally, which when viewed through our Smart Glasses and AR products create virtual images that appear comparable in size to that of a computer monitor or a large-screen television. This includes the representative forms such as augmented reality (AR), mixed reality (MR) and virtual reality (VR) and the areas interpolated among them. Extended reality (XR) is a term referring to all real-and-virtual combined environments. Their wearable display products cover the entire spectrum from “the complete real” to “the complete virtual” in the concept of reality–virtuality.

They believe that their waveguide optics and display engines offer a number of significant advantages over other wearable display solutions, including higher contrast, greater power efficiency, less weight, more compact size, and high brightness images for use outdoors. They also believe that our waveguide optics give them a substantial advantage over competitors’ optics, including other waveguides, because their solution allows them to produce optics that are fully transparent when off while also delivering the high brightness required for AR and enterprise Smart Glasses applications.

They  believe that key growth areas for us are the enterprise, medical, consumer electronics, OEM, defense and security markets. They are addressing most of these markets by developing and selling their own finished products and building a growing eco-system of software and services internally and with their value added resellers, or VARs, developers and end customers. Another potential channel to these markets they are developing includes supplying mass production of waveguide optics and display engines to select third parties to use in their products.

They believe that their waveguides and compact display engine technologies are a key differentiator for enabling next generation AR and Smart Glasses hardware for the enterprise and consumer segments because they will ultimately allow them to make HMDs nearly indistinguishable from regular eyeglasses.

They have developed their own intellectual property portfolio that includes patents, over 22 years of manufacturing know-how, software, proprietary processes, materials and equipment to create high performance waveguides, and near-eye display products. They believe our technology, intellectual property portfolio and position in the marketplace give them a leadership position in AR and Smart Glasses products and waveguide optics and display engine technology.

https://platform.twitter.com/embed-holdback-prod/Tweet.html?dnt=false&embedId=twitter-widget-0&features=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&frame=false&hideCard=false&hideThread=false&id=1614942790948888578&lang=en&origin=https%3A%2F%2Finsiderfinancial.com%2Fvuzi%2F&sessionId=fd72692cc5f903e58daeacc7915b3feb0dcdeb03&theme=light&widgetsVersion=2b959255e8896%3A1673658205745&width=550px

VUZI IS REBOUNDING HARD AND HAS CLOSED GREEN 10 OF THE LAST 12!

VUZIX RECEIVES OEM PURCHASE ORDERS FROM MULTIPLE DEFENSE AND COMMERCIAL CUSTOMERS

ROCHESTER, N.Y., Jan. 10, 2023 /PRNewswire/ — Vuzix® Corporation (NASDAQ: VUZI), (“Vuzix” or, the “Company”), a leading supplier of Smart Glasses and Augmented Reality (AR) technology and products, is pleased to announce the receipt of multiple OEM purchase orders for engineering services and products from three previously undisclosed defense firms and one previously undisclosed commercial customer. These orders, which were all received during the second half of 2022 and partially or fully shipped against before year end, are expected to expand in size over time to the extent each of these programs progresses. A brief description of each of these firms, the names of which cannot be disclosed at this stage of development, and the intended use cases for are as follows.

Vuzix has received multiple OEM orders for its waveguides, displays and systems.

A multinational electronics contract manufacturer has placed multiple orders for Vuzix waveguides and displays to support its development and manufacture of unique vision-based AR glasses.

A US-based leader in technologically advanced and intelligent solutions for the global aerospace and defense industry has given Vuzix an engineering services contract to support the development of a lightweight heads-up display (HUD) replacement for technologies previously supplied by a China-based company. This firm, a top 10 defense contractor, is the incumbent supplier for several existing programs and has turned to Vuzix as a US-based manufacturer of waveguide and display technologies.

A US-based supplier of protective armor and head systems, as well as innovative power supply and management solutions for military and tactical operators worldwide, has placed an order for Vuzix hardware technologies that will support their efforts to design several prototype display systems for the US Navy. Naval teams are currently using ruggedized Android phones but want to move the display to the helmet using Vuzix display technology. This customer plans to deliver its prototypes to the US Navy in pursuit of a design selection that, if successful, could result in volume production contracts over the next several years.

A US-based global leader in personal protection and situational awareness solutions for defense forces, emergency responders, and industrial personnel, has placed an order for Vuzix waveguides and projectors with the objective of adding smart capabilities to their helmet solutions via inclusion of a HUD.

“Our OEM business has continued to steadily expand in 2022 as more and more defense, consumer and enterprise firms are turning to Vuzix for its advanced low-cost waveguide and display solutions, solutions that are designed and manufactured in the United States. With some of these defense firms, we are already discussing much larger development and supply contracts for 2023,” said Paul Travers, President and Chief Executive Officer at Vuzix. “These new relationships further demonstrate the emerging presence of our advanced technologies in next generation system designs.”

___________

data:text/html;https://www.youtube.com/embed/tziACJVqwUI?autoplay=1;base64,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

The Blade works as a standalone headset and can be connected to the internet via Wi-Fi, but it can also be paired over Bluetooth with an iPhone or Android device to mirror notifications and display photos and videos. It has a battery life of anywhere from two to 12 hours, the company claims, depending on whether you’re using it mostly for notifications or for more intensive applications like accessing the web via Alexa, playing games, or using the front-facing, 8-megapixel camera. To maneuver the device’s interface, you can use an internal voice control system that’s separate from Alexa, or you can use a series of multi-fingered swipes on the right side of glasses frame.

SALES PROGRESS

MEDICAL APPLICATIONS

VUZIX INTRODUCED ITS NEW AWARD WINNING ULTRALITE™ SMART GLASSES PLATFORM AT CES 2023

VUZIX ULTRALITE

Vuzix Ultralight™ Smart Glasses

AN OEM SMART GLASSES PLATFORM LIKE NO OTHER

The Vuzix Ultralite™ AR Smart Glasses Platform is a go-to-market ready, turnkey offering designed to fast track client AR solutions into production. Weighing in at a mere 38 grams, super power-efficient with up to 48 hours of run time on a single charge, and packing an impressive waveguide to display information from your phone hands-free to your eye, Vuzix Ultralite OEM platform is a blueprint for the world’s most fashion forward smart glasses. 

TRUSTED PROPRIETARY TECHNOLOGY FROM VUZIX

Advanced monocular waveguide optics, combined with our custom micro display engine, create a crisp, transparent image that can deliver all the important information on a user’s smartphone/watch, hands-free right before their eyes. Prescription ready with multiple sizes and an array of component combinations, the Vuzix Ultralite OEM platform makes available our extensive manufacturing capabilities and patent-protected leadership position in both waveguides and custom display engine solutions.

THE POWER TO DEPLOY YOUR AR SOLUTION AT SCALE

The Vuzix Ultralite OEM platform is designed to enable leading consumer technology firms to accelerate deployment of AR smart glasses solutions to the masses. Our manufacturing facility in Rochester NY is an ISO 9001:2015 facility that includes Class 6 and Class 7 clean room enclosures ensuring the highest levels of product quality and precision. All Vuzix OEM components are designed and manufactured in the USA, leveraging proprietary advancements in waveguide technology protected by our extensive IP portfolio. 

VUZIX ULTRALITE OEM PLATFORM BENEFITS

  • Puts your smartphone’s alerts, messages, and custom applications content heads up in front of your vision.
  • Get hands free access to important information, from language translation and closed captioning, to directions, to health and workout status, to messaging and much, much more.
  • Designed to work hand to glove with both Android and iOS phones, Vuzix Ultralite is the reference design for the perfect smartphone accessory.
  • Virtually endless configuration options around size, color, form factor and optical setup to set your solution apart.
  • Vuzix is working with the world’s leading consumer electronic technology companies to bring lightweight, affordable smart glasses solutions to market.  

VUZIX LEASES NEW MANUFACTURING SPACE TO SUPPORT THE EXPANSION OF ITS WAVEGUIDE PRODUCTION CAPACITY

Vuzix is eligible for up to $1 million from Empire State Development to support regional job creation through the Excelsior Jobs Tax Credit Program

WEST HENRIETTA, NY, November 3, 2022 – Vuzix® Corporation (NASDAQ: VUZI), (“Vuzix” or, the “Company”), a leading supplier of Smart Glasses and Augmented Reality (AR) technology and products, is pleased to announce that the Company has signed a new lease for floor space in a building adjacent to its West Henrietta headquarters for the express purpose of expanding its waveguide production capacity.

The lease is for partial occupancy of the building with an option to lease the entire building as needed for future phase expansion. Waveguide production equipment has already been purchased and will be installed and prepped for volume output over the next six months in this new ISO 9001 facility. The expanded facility will feature a Class 1000 cleanroom in addition to housing the optics and manufacturing equipment needed to support Vuzix’ propriety waveguide development process. This action is expected to increase the Company’s annual production capacity to well over one million units during the first half of 2023.

Related to this expansion, Vuzix is eligible for up to $1 million through Empire State Development’s (ESD) Excelsior Jobs Tax Credit program in exchange for job creation commitments. ESD is New York’s State’s chief economic development agency and has approved this level of support for Vuzix subject to its program rules.

“The optical, weight and power advantages offered by Vuzix waveguides are well appreciated by our partners in enterprise, defense, consumer and other markets. With the growing demand for custom configured waveguides emerging for us, it is an opportune time for Vuzix to be ramping its waveguide production capacity,” said Paul Travers, President and CEO of Vuzix. “All Vuzix OEM solutions are designed and manufactured in-house here in New York State, protected by a deep IP portfolio, and supported by facilities equipped to supply at scale and at a cost competitive price for key customers.”

NEWS

Jan 10, 2023 8:30am EST

VUZIX RECEIVES OEM PURCHASE ORDERS FROM MULTIPLE DEFENSE AND COMMERCIAL CUSTOMERS 

Jan 06, 2023 9:00am EST

VUZIX BLADE POWERS XANDER’S REAL-TIME CAPTIONING XANDERGLASSES FOR THE DEAF AND HARD OF HEARING 

Jan 03, 2023 9:26am EST

VUZIX TO SHOWCASE AT CES 2023 ONE OF THE INDUSTRY’S BROADEST AND MOST COMPETITIVE LINES OF AR SMART GLASSES 

Dec 21, 2022 8:01am EST

VUZIX SIGNS DISTRIBUTION AGREEMENT WITH ELMARK AUTOMATION AND RECEIVES INITIAL VOLUME SMART GLASSES ORDER 

Dec 19, 2022 10:00am EST

FUJITEC COMMENCES FULL-SCALE DEPLOYMENT WITHIN JAPAN OF VUZIX SMART GLASSES TO SUPPORT WORKFORCE MAINTENANCE AND TRAINING 

Dec 09, 2022 10:00am EST

VUZIX TO DISCUSS THE AR INDUSTRY AND ITS SMART GLASSES SOLUTIONS AT THE OPPENHEIMER 5G VIRTUAL SUMMIT ON DECEMBER 13 

Dec 01, 2022 10:32am EST

KYOCERA AND TOKYO MEDICAL DENTAL UNIVERSITY DEVELOP CARDIAC REHABILITATION THERAPY EMPLOYING VUZIX BLADE SMART GLASSES 

Nov 17, 2022 7:00am EST

VUZIX TO INTRODUCE ITS NEW AWARD WINNING ULTRALITE™ SMART GLASSES PLATFORM AT CES 2023 

Nov 09, 2022 4:02pm EST

VUZIX REPORTS DOUBLE DIGIT REVENUE GROWTH IN Q3 2022 

Nov 03, 2022 1:35pm EDT

VUZIX ANNOUNCES GENERAL AVAILABILITY OF M400C SMART GLASSES

Nov 03, 2022 10:00am EDT

VUZIX LEASES NEW MANUFACTURING SPACE TO SUPPORT THE EXPANSION OF ITS WAVEGUIDE PRODUCTION CAPACITY 

Nov 01, 2022 9:15am EDT

VUZIX ACQUIRES SAP SOFTWARE SOLUTION PROVIDER MOVIYNT™ 

Oct 19, 2022 1:30pm EDT

SALES VETERAN BILL BELTZ JOINS VUZIX IN THE NEW POSITION OF VICE PRESIDENT OF GLOBAL SALES 

Oct 19, 2022 1:20pm EDT

VUZIX TO DEMONSTRATE ITS INDUSTRY-LEADING SMART GLASSES SOLUTIONS AT UPCOMING AES AND AWE-EU TRADE SHOW CONFERENCES 

Oct 18, 2022 2:00pm EDT

VUZIX SCHEDULES CONFERENCE CALL TO DISCUSS THIRD QUARTER 2022 FINANCIAL RESULTS AND BUSINESS UPDATE 

Oct 17, 2022 8:30am EDT

VUZIX BLADE SMART GLASSES SUPPORT XPERTINC’S CLOSED CAPTIONING C-SOUND SOLUTION FOR THE DEAF AND HEARING IMPAIRED 

Oct 11, 2022 1:10pm EDT

VUZIX EXPANDS ASIA-PACIFIC PRESENCE WITH VOLUME SMART GLASSES ORDER FROM DISTRIBUTION PARTNER HONGKE 

Oct 06, 2022 1:45pm EDT

VUZIX SMART GLASSES SELECTED TO SUPPORT NSION’S SEAMLESS SITUATIONAL AWARENESS SOLUTION FOR DOD AND FIRST RESPONDERS 

Oct 03, 2022 10:45am EDT

HODEI TECHNOLOGY PARTNERS WITH VUZIX TO SUPPORT ITS NEW KLABRA PLATFORM AND PLACES INITIAL VOLUME PURCHASE ORDER 

Sep 28, 2022 10:50am EDT

VUZIX ANNOUNCES GENERAL AVAILABILITY OF BLADE 2™ SMART GLASSES

MANAGEMENT 

Paul J. Travers

PAUL J. TRAVERS

CEO, President and Director

Paul Travers is the founder of Vuzix and has served as our President and Chief Executive Officer since 1997 and as a member of our Board of Directors since November 1997. Prior to the formation of Vuzix, Mr. Travers founded both e-Tek Labs, Inc. and Forte Technologies Inc. He has been a driving force behind the development of our products. With more than 30 years’ experience in the consumer electronics field, and 26 years’ experience in the virtual reality and virtual display fields, he is a nationally recognized industry expert. He holds an Associate degree in engineering science from Canton, ATC and a Bachelor of Science degree in electrical and computer engineering from Clarkson University.

Grant Russell

GRANT RUSSELL

CFO, Executive Vice President, Treasurer and Director

Grant Russell has served as our Chief Financial Officer and Executive Vice President since 2000 and as a member of our Board of Directors since April 2009. From 1997 to 2004, Mr. Russell developed and subsequently sold a successful software firm and a new concept computer store and cyber café. In 1984, he co-founded Advanced Gravis Computer (Gravis), which, under his leadership as President, grew to become the world’s largest PC and Macintosh joystick manufacturer with sales of $44 million worldwide and 220 employees. Gravis was listed on NASDAQ and the Toronto Stock Exchange. In September 1996 it was acquired by a US-based Fortune 100 company via a successful public tender offer. Mr. Russell holds a Bachelor of Commerce degree in finance from the University of British Columbia and is both a US Certified Public Accountant and a Canadian Chartered Professional Accountant.

PETE JAMESON

COO

Pete Jameson was named Chief Operating Officer (COO) of Vuzix in January 2022, having served as General Manager since joining the company in January 2021. Mr. Jameson brings a wealth of operating experience to his new position. He previously served as COO of Osterhout Design Group (ODG), a leading wearable technology company that developed and manufactured mobile, self-contained and lightweight head-worn mixed reality smart glasses with photo-realistic imagery. Prior to ODG, Mr. Jameson was a 20-year executive at Eastman Kodak where he was a founding leader of Kodak’s multi-billion-dollar Digital Camera Business including General Manager and VP of the Digital SLR and Professional Digital Capture Group that created the world’s first digital SLR cameras, General Manager of Kodak’s Commercial Imaging Business in Europe, Africa and the Middle East and General Manager and VP of Kodak’s Digital Devices Group. He holds a Bachelor of Science Electrical Engineering degree from Union College and a Master of Business Administration degree from the University of Rochester Simon School of Business.

Eric Black

ERIC BLACK

General Counsel

Eric Black was named General Counsel of Vuzix in March 2022. Mr. Black brings a wealth of legal experience to his new position. While serving as in-house for other private and public technology companies, Mr. Black developed extensive experience in supporting business development and operational optimization by developing processes/workflows, negotiating complex contracts, advising on mergers and acquisitions, and informing business strategies that strengthen compliance and facilitate consistent growth. Mr. Black was previously named one of Rochester’s “Forty Under 40” by the Rochester Business Journal in 2006 and one of Rochester’s Top Counsel by the Rochester Daily Record in 2019. He holds a Bachelor of Economics degree from the University of Rochester and a Doctor of Jurisprudence degree from the University of Virginia School of Law.

SHANE PORZIO

Vice President Engineering

Shane Porzio has been with the Company for more than ten years and has more than 13 years of experience in architecture of systems and designs for hardware and software. His previous employment was at Lockheed Martin where he served as a Hardware Engineer. Mr. Porzio has BS in Computer Engineering Technology from Rochester Institute of Technology and his MS in Computer Science from Rochester Institute of Technology.

BILL BELTZ

Vice President of Global Sales

Bill Beltz brings a wealth of general management and sales experience to his new position. Prior to joining Vuzix, he served as Vice President of Sales at Snap One, a leading manufacturer and distributor of smart living technology. Prior to Snap One, he held sales and management positions of increasing responsibility at both NCR Corporation, a Fortune 500 software, consulting and technology company providing professional services and electronic products, and Radiant Systems, a provider of technology to the hospitality and retail industries that was subsequently acquired by NCR Corporation.

Sincerely,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY A THIRD PARTY, LEGENDS MEDIA LLC  FOR A ONE DAY VUZI AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS, LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

NEW NASDAQ PROFILE: SYTA

SYTA PROFILE

Siyata Mobile Inc.

OUR NEW PROFILE IS:    (NASDAQ: SYTA)

(TSXV: SIM) 

SYTA NEWS: Siyata’s Next Generation Push-to-Talk Over Cellular SD7 Device to be Launched Across T-Mobile IoT Data Network.

  • T-Mobile is the second-largest wireless carrier in the U.S. with more than 111.7 million customers1
  • SD7 now approved on all major U.S. wireless carriers including AT&T Inc., Verizon Communications Inc. and United States Cellular Corporation (UScellular™)
  • Siyata believes that industry-changing Push-to-Talk Over Cellular device offers a far superior solution to competitive Land-Based Radio (LMR) technologies2
  • SD7 targets the multi-billion-dollar first responder and enterprise markets

SYTA OPERATES IN THE UNITED STATES, CANADA, EUROPE, AUSTRALIA, MIDDLE EAST

SIYATA GIVES CARRIERS THE ABILITY TO ACTIVATE A SIM CARD AND GENERATE INCOME OTHERWISE NOT CAPTURED WITH CUSTOMERS WHO USE LMR

REVENUES FOR THE QUARTER ENDING SEPTEMBER 30, 2022 WERE $2,567,885 COMPARED TO $1,218,875 FOR THE 3RD QUARTER OF 2021

SIYATA MOBILE INC. (NASDAQ: SYTA) SECURES CHANNEL PARTNERSHIPS WITH 2 OF THE 3 LARGEST MOBILE CARRIER PROVIDERS IN THE US

______________

CHECK OUT THE INVESTOR PRESENTATION HERE

_____________________________________________

Hello Everyone,

We have another exciting Nasdaq profile for todays session.

It is not often that we see a company trading on a National exchange at this price point.

Pull up SYTA immediately.

Siyata Mobile Inc. (NASDAQ: SYTA) (TSXV: SIM) is a leading global developer and provider of Push-to-Talk Over Cellular (“PTT/PoC”) systems for enterprise customers. The company specializes in connected vehicle products for professional fleets and markets its products under the Uniden® Cellular brand.

Since its inception in 2012, Siyata has amassed a customer base that includes cellular operators, commercial vehicle technology distributors, and fleets of all sizes in Canada, the U.S., Europe, Australia and the Middle East.

Recognized by the Toronto Venture Stock Exchange in 2018 as a Venture Top 50 Company, Siyata aims to deliver the highest quality and most technologically advanced mobile communication devices for global corporate workforces, fleets, homes and buildings.

The company has long been an industry pioneer, delivering the world’s first 3G connected vehicle device as well as the world’s first 4G/LTE vehicle-mounted smartphone for First Responders and commercial fleets and vehicles, thereby creating a new category in the cellular device market with a dedicated smartphone tailor-made for the commercial vehicle market.

Siyata’s suite of technology includes numerous PTT and legacy devices, as well as cellular boosters designed to improve cellular signals in corporate warehouses, government embassies, retirement home campuses, banks and manufacturing plants.

The company’s flagship product, the Uniden UV350, is the world’s first vehicle-mounted 4G/LTE smartphone with crystal clear quality, carrier grade PTT, voice, text, video and data applications built into a single device. Specifically designed for First Responder and commercial fleet vehicles, the UV350 runs on cellular LTE networks that provide nationwide and global coverage, replacing traditional single purpose two-way radios that require a monthly fee and limited network coverage.

The Uniden UV350 is currently available through Bell Mobility, Canada’s largest LTE network and PTT community, as well as AT&T in the U.S. Further expanding its availability, Siyata is completing network approval with another U.S. Tier 1 operator to launch the UV350 in Q3 2019.

The company reported 3rd quarter 2022 results on November 10th which demonstrated strong growth for one of its product lines. Revenues for the quarter ending September 30, 2022 were $2,567,885 compared to $1,218,875 for the 3rd quarter of 2021. This 111% increase over the prior year period was primarily due to the increase in the sale of rugged devices including the SD7 rugged handset during the quarter. Sales related to rugged handsets and accessories increased 588% to approximately $1.9 million.

Despite Siyata’s small size, no other competitor offers as comprehensive of a portfolio of products. Siyata Mobile Inc. (Nasdaq: SYTA) provides disruptive solutions aimed at the Push-to-talk-over-Cellular (PoC) industry, with three complementary product categories targeted to the same core channels and customers. (5)Large global telecommunications customers provide potential rapid entry into a $50 billion North American market. (6)

No photo description available.

GAME-CHANGING CHANNEL PARTNERS:

With a combined existing base of over 343 million subscribers, having AT&T and Verizon as channel partners could prove to be a monumental catalyst for Siyata Mobile Inc. (Nasdaq: SYTA) as they roll out their game-changing Push-to-Talk Over Cellular devices. (22)(23)

ANALYST VALUATION:

Thomas Kerr, CFA is a Senior Equity Research Analyst at Zacks Small-Cap Research with over 25 years of securities industry experience in the Technology, Consumer, Industrials, Med-Tech, Healthcare & Biotechnology sectors recently assigned a $2.50 valuation on Siyata Mobile Inc. (Nasdaq: SYTA) on November 14th, 2022.(1)

MASSIVE BOUNCE POTENTIAL: 

Shares of Siyata Mobile Inc. (Nasdaq: SYTA) recently bounced off its 52-week low of $.1051 on 11/09/2022 and with a 52-week high of $ 5.4763 set on 12/09/2021 there could be over 5,110% in upside potential if (SYTA) climbs back to that 52-week high level. (2) To be fair, a 5,110% move back to the 52-week high is not expected, but the potential should be noted.

GROWTH TRAJECTORY: 

In general, nano-cap companies have market capitalizations of less than $50 million.(3)By identifying companies when they are still small, you have the opportunity to witness the front end of a potentially massive growth curve.(3)According to MarketWatch.com, as of 12/8/22, Siyata Mobile Inc. (Nasdaq: SYTA) has a market cap of less than $2.5 million.(4)

ROBUST REVENUE GROWTH: 

The company reported 3rd quarter 2022 results on November 10th which demonstrated strong growth for one of its product lines. Revenues for the quarter ending September 30, 2022 were $2,567,885 compared to $1,218,875 for the 3rd quarter of 2021. This 111% increase over the prior year period was primarily due to the increase in the sale of rugged devices including the SD7 rugged handset during the quarter. Sales related to rugged handsets and accessories increased 588% to approximately $1.9 million.

MARKET DISRUPTOR: 

Despite Siyata’s small size, no other competitor offers as comprehensive of a portfolio of products. Siyata Mobile Inc. (Nasdaq: SYTA) provides disruptive solutions aimed at the Push-to-talk-over-Cellular (PoC) industry, with three complementary product categories targeted to the same core channels and customers. (5)Large global telecommunications customers provide potential rapid entry into a $50 billion North American market. (6)

MAJOR CATALYSTS

  • Recognized in 2018 by the Toronto Venture Stock Exchange as a Top 50 Company
  • Siyata is the first and only company to offer a dedicated in-vehicle cellular solution for the next generation of fleet communication in North America
  • New revenue streams are opening up in North American with nationwide cellular networks like Bell Mobility and two Tier 1 U.S. cellular carriers
  • Future recurring revenue from third-party fleet application sales
  • Uniden UV350 has already been launched with Bell Canada and AT&T
  • Additional Tier 1 U.S. carrier agreement expected in Q3 2019
  • North America presents very few to no competitors for Siyata Mobile
  • Over 1 million rugged cellular devices are sold  in North America annually
  • According to the United States Department of Transportation, in 2016 there were 3.5 million First Responder vehicles and 9.7 million commercial vehicles throughout the United States
  • Very strong treasury, excellent liquidity on the stock
  • All-in-one device is available for approximately USD$1,000, replacing expensive USD$5,000-$10,000 equipment (lower Capex and opex)
  • Participating in a $15 billion-dollar market with no direct competition

Siyata Mobile Inc. (Nasdaq: SYTA) aims to be the global leader in the rapidly growing Push-to-Talk Over Cellular (PoC) industry by disrupting the legacy Land Mobile Radio (LMR) industry with Next Generation Cellular Technology.

Siyata will be competing with companies that have $10b – $40B Market Values.

But this is not a “David vs Goliath” situation…

In fact, Siyata is in a “Goliath vs Goliath” situation as they already have 2 of the largest mobile carriers (AT&T and Verizon) as their channel partners.

Could you imagine what this could mean for a company with a market cap of less than $2.5 million dollars as of 12/8/22(4)?

AT&T, Verizon, and other cellular carriers are competing for the lucrative Land Mobile Radio (LMR) market and Siyata Mobile Inc. (Nasdaq: SYTA) and its technology could be the secret ingredient…

This is similar to when the Intel Corporation started its now famous “Intel Inside” marketing campaign.

Before the “Intel Inside” campaign, Intel had been largely unknown to consumers. The company had a reputation for its technical prowess and quality among original equipment manufacturers, but it had not seen much need to cultivate a similar renown among end users. (26)

That began to change in the late 1980s — the PC market was creating a huge demand for central processing units, and with that came a new imperative for Intel to explain the desirability of its products to lay consumers.(26)

Intel’s response to that imperative, the “Intel Inside” campaign, would make advertising history, turn Intel into a household brand name and create a valuable shortcut through which OEMs could signal the quality of their products to customers.(26)

Siyata could potentially be the “Siyata Inside” that the Push-to-Talk Over Cellular market is missing.

With a combined existing base of over 343 million subscribers, having AT&T and Verizon as channel partners could prove to be a monumental catalyst for Siyata Mobile Inc. (Nasdaq: SYTA) as they roll out their game-changing Push-to-Talk Over Cellular devices. (22)(23)

SIYATA MOBILE INC. (NASDAQ: SYTA) ANNOUNCES CHANNEL PARTNERSHIP WITH VERIZON COMMUNICATIONS INC.

On June 7, 2022 – Siyata Mobile Inc. (Nasdaq: SYTA) announced that Verizon Communications Inc., the largest mobile operator in the U.S. with 143.0 million total retail connections as of Q1 2022, has fully integrated Siyata’s rugged SD7 device into their network.

As a Siyata channel partner, Verizon will sell the SD7 to their broad enterprise customer base as well as their first responder network of 4.5 million connections with over 30,000 public-safety agencies.

The SD7 was developed to disrupt and replace the multi-billion-dollar Land Mobile Radio (LMR) industry.

“We are thrilled to be working with Verizon, the largest cellular network in the U.S., as we roll out our game-changing SD7 device,” said Siyata CEO Marc Seelenfreund.

“With superior coverage, improved functionality, and low start-up and operating costs, the SD7 is the perfect upgrade from land-based radio technologies, delivering a far superior solution to a multi-billion dollar industry. Now through Verizon, we can reach even more first responders and enterprise personnel with a rugged device that can operate reliably in tough working environments.”(22)

The SD7 brings push-to-talk communications into the 21st century and enables first Responders and enterprise clients a simple easy-to-use rugged Android based Push-To-Talk (PTT) device with excellent sound quality that operates over the high bandwidth 4G LTE network, providing consistent connectivity across the nation and internationally. (22)

Its IP68 rating, resistance to water and dust, drop protection, and robust battery make it well suited for use in harsh environments. Importantly, there is no need to invest in infrastructure such as radio towers or repeaters.(22)

The SD7 allows first responders as well as secondary support personnel to quickly connect and coordinate on unified public cellular networks in North America and international markets.(22)

SIYATA MOBILE INC. (NASDAQ: SYTA) ANNOUNCES CHANNEL PARTNERSHIP WITH AT&T INC.(23)

On June 27, 2022, Siyata Mobile Inc. (Nasdaq: SYTA) announced that the SD7 rugged device is now commercially available on and will be sold through the FirstNet® network and to AT&T Inc.’s enterprise channels.

AT&T is one of America’s largest mobile operators with 201.8 million mobility subscribers, as of Q4 2021.

As a Siyata channel partner, AT&T will offer the SD7 device and accessories to their extensive­­ U.S. enterprise customer base.

The SD7 was developed to disrupt and replace the multi-billion-dollar Land Mobile Radio (LMR) industry and is perfectly suited for AT&T’s enterprise customers who require a rugged device that can operate reliably in harsh working environments.

AT&T has approximately 3 million business customers (as of Q4 2021) in verticals including: construction, energy and utility, transportation and logistics, manufacturing, government & defense, travel & hospitality.

“The momentum continues to build for our game-changing SD7 device and we are thrilled to be commercially launching on FirstNet® and AT&T’s network,” said Siyata CEO Marc Seelenfreund.

“With superior coverage, improved functionality, and low start-up and operating costs, the SD7 is the perfect upgrade from land-based radio technologies, delivering a far superior solution to a multi-billion dollar industry.”

The SD7 brings push-to-talk communications into the 21st century and enables first Responders and enterprise clients a simple easy-to-use rugged Android based Push-To-Talk (PTT) device with excellent sound quality that operates over the high bandwidth 4G LTE network, providing consistent connectivity across the nation and internationally.

NEWS

  • ACCESSWIRE•last monthSIYATA MOBILE ADDS UK AND IRELAND DISTRIBUTOR RADIOTRADER FOR SD7 DEVICES AND VK7 ACCESSORIESSiyata Mobile Inc. (NASDAQ SYTA)(NASDAQ:SYTAW)(“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (“PoC”) devices and cellular signal booster systems, has added RadioTrader, the UK and Ireland’s premier two-way radio supplier, to distribute the SD7 ruggedized, mission critical PoC device and VK7 vehicle kit accessary.ACCESSWIRE•2 months agoSIYATA MOBILE’S SD7 DEVICE LAUNCH ON BELL MOBILITY WIRELESS NETWORK EXPANDS NEXT-GENERATION PUSH-TO-TALK OVER CELLULAR SERVICES ACROSS CANADASiyata Mobile Inc. (NASDAQ:SYTA)(NASDAQ:SYTAW)(“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (“PoC”) devices and cellular signal booster systems, is pleased to announce that Bell Mobility Inc., a leading wireless operator in Canada with more than 10 million subscribers and a division of Bell Canada, will launch Siyata’s rugged SD7 device onto their network in the fourth quarter 2022.
  • Zacks Small Cap Research•2 months agoSYTA: UPDATE: SIYATA REPORTED 2022 3RD QUARTER FINANCIAL RESULTS WHICH SHOWED HIGH REVENUE GROWTH RATES COMPARED TO THE PRIOR YEAR PERIOD.By Thomas Kerr, CFA NASDAQ:SYTA READ THE FULL SYTA RESEARCH REPORT Siyata Mobile (NASDAQ:SYTA) reported 3rd quarter 2022 results on November 10 th which demonstrated strong growth for the SD7 rugged handset. Revenues for the quarter ending September 30, 2022 were $2,567,885 compared to $1,218,875 for the 3rd quarter of 2021. This 111% increase over the prior year period was primarily due to the
  • ACCESSWIRE•2 months agoCORRECTING AND REPLACING: SIYATA MOBILE ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTSSiyata Mobile Inc.(NASDAQ:SYTA)(NASDAQ:SYTAW) (“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (PoC) devices and cellular signal booster systems, announced its financial results for the three months ended September 30, 2022.
  • ACCESSWIRE•2 months agoSIYATA MOBILE ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTSSiyata Mobile Inc.(NASDAQ:SYTA)(NASDAQ:SYTAW) (“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (PoC) devices and cellular signal booster systems, announced its financial results for the three months ended September 30, 2022.
  • ACCESSWIRE•2 months agoSIYATA MOBILE TO HOST THIRD QUARTER 2022 FINANCIAL RESULTS CALL ON NOVEMBER 11 AT 8 A.M. ESTSiyata Mobile Inc.(NASDAQ:SYTA)(NASDAQ:SYTAW) (“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (PoC) devices and cellular signal booster systems, announced that it will host its third quarter 2022 financial results conference call on Friday, November 11, at 8 a.m. EST. Following management’s formal remarks, there will be a question-and-answer session.
  • ACCESSWIRE•2 months agoSIYATA MOBILE WELCOMES TELECOM INDUSTRY VETERAN DAN LEECH TO ITS SALES TEAMSiyata Mobile Inc. (NASDAQ:SYTA/SYTAW) (“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (PoC) devices and cellular signal booster systems, today announced the addition of telecom industry veteran Dan Leech to the Company’s sales team.
  • ACCESSWIRE•2 months agoSIYATA’S SD7+ CELLULAR BODY CAMERA DEVICE WILL SOON BE POWERED BY VISUAL LABSSiyata Mobile Inc. (NASDAQ:SYTA)(NASDAQ:SYTAW) (“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (PoC) devices and cellular signal booster systems, today announces the SD7+ rugged mission-critical push-to-talk (PTT) device will soon be powered with Visual Labs Inc.’s (“Visual Labs”) innovative body camera software.
  • ACCESSWIRE•3 months agoSIYATA TO PRESENT AT THINKEQUITY INVESTOR CONFERENCE ON OCTOBER 26Siyata Mobile Inc.(NASDAQ:SYTA)(NASDAQ:SYTAW) (“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (PoC) devices and cellular signal booster systems, today announced that Daniel Kim, VP Corporate Development of the Company, will attend and present at the ThinkEquity investor conference taking place at The Mandarin Oriental Hotel in New York on Wednesday, October 26, 2022.
  • ACCESSWIRE•3 months agoSIYATA ANNOUNCES CLOSING OF $4.0 MILLION REGISTERED DIRECT OFFERINGSiyata Mobile Inc. (NASDAQ:SYTA)(NASDAQ:SYTAW) (“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (PoC) devices and cellular signal booster systems, today announced the closing of its previously announced $4.0 million registered direct offering.
  • ACCESSWIRE•3 months agoSIYATA ANNOUNCES PRICING OF $4.0 MILLION REGISTERED DIRECT OFFERINGSiyata Mobile Inc.(Nasdaq:SYTA/SYTAW) (“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (PoC) devices and cellular signal booster systems, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase approximately $4.0 million of its common shares and pre-funded warrants in lieu thereof in a registered direct offering and warrants to purchase common shares in a
  • ACCESSWIRE•4 months agoSIYATA MOBILE’S UNIDEN(R) CELLULAR BOOSTER KITS AND ACCESSORIES TO BE PURCHASED BY U.S. NAVYSiyata Mobile Inc.(NASDAQ:SYTA)(NASDAQ:SYTAW) (“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (PoC) devices and cellular signal booster systems, is pleased to announce that it has received a purchase order from a federal government contractor who will provide Uniden® cellular booster kits and accessories to the U.S. Navy.
  • ACCESSWIRE•4 months agoSIYATA LAUNCHES CRISISGO PANIC APP INTEGRATION FOR SD7, PROVIDING INSTANT COMMUNICATION BETWEEN TEACHERS AND FIRST RESPONDERS TO IMPROVE CRISIS RESPONSE TIMESSiyata Mobile Inc. (Nasdaq:SYTA/SYTAW)(“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (PoC) devices and cellular signal booster systems, is pleased to announce that its SD7 rugged mission-critical push-to-talk (MCPTT) device is now integrated with CrisisGo Inc.’s (“CrisisGo”) Panic App, giving teachers instant access to first responders with a single push of a button.
  • ACCESSWIRE•4 months agoSIYATA MOBILE ANNOUNCES RECEIPT OF NASDAQ NOTIFICATION REGARDING MINIMUM BID PRICE DEFICIENCYSiyata Mobile Inc.(Nasdaq:SYTA, SYTAW) (“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (PoC) devices and cellular signal booster systems, today announced that the Company had received a notification letter dated August 26, 2022 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that it is currently not in compliance with the minimum bid price requirement set forth

______________________________

MANAGEMENT TEAM

MARC SEELENFREUND – CEO

Founder and CEO of Siyata . Prior to establishing Siyata Mr. Seelenfreund was a VP at Sunrise Corporation in New York focusing on financing publicly traded technology companies. Mr. Seelenfreund has a law degree and is a board member at a leading private university.

GERALD BERNSTEIN – CFO

Mr. Bernstein spend 20 years focusing on private equity financing and tax efficient corporate structuring in multi-jurisdictional arenas. Mr. Bernstein holds a Bachelor of Commerce as well as a Graduate Diploma in Public Accountancy- both from McGill University. Member of the Canadian Institute of Chartered Accountants since 1987 and a professional chartered accountant.

GLENN KENNEDY – VP SALES

Mr. Kennedy has over 25 years of sales experience in the telecommunications industry. Prior to joining Siyata in 2016, Mr. Kennedy has managed sales nationally for Motorola Canada, HTC Communications Canada and Sonim Technologies. Mr. Kennedy holds an Bachelor of Arts in Honors Business Administration from the Richard Ivey School of Business at the University of Western Ontario.

DIRECTORS

PETER GOLDSTEIN, CHAIRMAN OF THE BOARD

With over 30 years of diverse and global entrepreneurial, client advisory and capital market experience, Mr. Goldstein has a successful track record in leading and building companies in the capital markets. Mr. Goldstein has achieved capital market objectives by drawing on his strengths in M&A, strategic planning and transaction structuring, as well as his own entrepreneurial success. He has steered and completed initial public offerings (IPO), uplisting and reverse merger transactions, secured private placements and designed successful crowdfunding campaigns. Mr. Goldstein advised the Company on its recently upsized $12.6 Million U.S. Initial Public Offering and listing on the NASDAQ.

STEPHEN OSPALAK, BOARD MEMBER

Over 20 years in telecom, currently SVP Marketing & Operations at BMG Inc. Served as interim CEO for AiTelecom; Global Integration Officer for Virgin Management Inc.; Canadian VP & Board Advisor for Brightstar, and as SVP Operations at Iusacell. Served as VP of Products & Services at Telus Communications Inc. responsible for an annual spend > $US 1billion in wireless & wireline equipment. Led the planning and execution of Clearnet’s market debut and nationwide launch of the iDEN and PCS Cellular services, setting the North American PCS launch record. Held management positions at AT&T.

MICHAEL KRON, BOARD MEMBER

Mr. Kron has over 20 years of experience in investment and corporate finance, currently chairman and CFO at AnywhereCommerce Inc. He also co-founded Zellers Optical Centers and played a key role in the sale to Vision Associates of Atlanta. He was the co-founder and CFO of Miazzi Ventures where he founded Mamma.com Inc and later sold to Intasys Corporation at a $44M valuation. Mr. Kron holds a Bcomm from Concordia University as well as a Graduate Diploma in Public Accountancy from McGill University. He has been a member of the Canadian Institute of Chartered Accountants since 1987.

LOURDES FELIX, BOARD MEMBER

Lourdes Felix is a corporate finance executive offering over fifteen years of combined experience in public accounting and in the private sector in building, leading, and advising corporations through complex restructurings. Ms. Felix was previously the controller for a mid-size public accounting firm for over seven years and was responsible for the operations and financial management of regional offices. Ms. Felix has been a Director of BioCorRx Inc. since March 7, 2013. Ms. Felix was appointed Chief Executive Officer of BioCorRx on November 9, 2020 and became Chief Financial Officer of BioCorRx on October 1, 2012. Ms. Felix was President of BioCorRx from February 26, 2020 until she resigned upon her appointment as CEO on November 9, 2020. Ms. Felix holds a Bachelor of Science degree in Business Management and Accounting from University of Phoenix.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY A THIRD PARTY, LIFEWATER MEDIA  FOR A ONE DAY SYTA AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS, LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Source 1:https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_11142022_SYTA_Kerr.pdf

Source 2: https://www.barchart.com/stocks/quotes/SYTA/price-history/historical

Source 3: https://www.finweb.com/investing/4-reasons-to-invest-in-a-nano-cap.html

Source 4: https://www.marketwatch.com/investing/stock/syta?mod=search_symbol

Source 5: https://www.siyatamobile.com/wp-content/uploads/2022/08/Siyata-Mobile-Investor-Presentation-Q3-2022-2022-08.pdf

Source 6: https://www.siyatamobile.com/wp-content/uploads/2021/11/SYTA-One-Pager_Nov-23-2021.pdf

Source 7: https://www.securitymagazine.com/articles/97324-private-mobile-networks-will-fuel-the-4th-industrial-revolution

Source 8: https://www.commercient.com/wp-content/uploads/2019/03/The-Fourth-Industrial-Revolution-The-Rise-Of-The-Intelligent-Era-2.jpg

Source 9: https://www.globenewswire.com/news-release/2022/10/21/2538979/0/en/Push-To-Talk-PTT-Market-Size-to-Reach-USD-59-81-Billion-by-2030-Future-Projections-Emerging-Technical-Advancements-Recent-Initiatives-and-Growth-Opportunities-Adroit-Market-Researc.html

Source 10: https://s27.q4cdn.com/906368049/files/design/zacks_scr.svg

Source 11: https://finance.yahoo.com/news/siyata-mobile-adds-uk-ireland-130000242.html

Source 12: https://www.siyatamobile.com/wp-content/uploads/2022/02/homepage-SD7-Front-v2.png

Source 13: https://www.siyatamobile.com/

Source 14: https://www.siyatamobile.com/wp-content/uploads/2020/09/booster_img.png

Source 15: https://www.amazon.com/Uniden-Cradle-Signal-Booster-Carriers/dp/B09MTY562X

Source 16: https://www.siyatamobile.com/uniden-uv350/

Source 17: https://www.siyatamobile.com/uniden-cp250/

Source 18: https://www.siyatamobile.com/uniden-ur5/

Source 19: https://schrts.co/iHhbBcPk

Source 20: https://tradesmith.com/educational/this-market-cap-strategy-is-crushing-the-nasdaq/

Source 21: https://www.siyatamobile.com/directors-officers/

Source 22: https://www.siyatamobile.com/siyata-launches-next-generation-push-to-talk-over-cellular-sd7-device-on-verizon-global-network/

Source 23: https://www.siyatamobile.com/siyatas-next-generation-push-to-talk-over-cellular-sd7-device-is-now-commercially-available-and-sold-through-firstnet-and-att-inc/

Source 24: https://www.cnet.com/a/img/resize/409f3c87a1c14d4edc95e1b423fd14061df0c9d7/hub/2014/10/31/64b38597-6e50-4566-8786-9d5e8cd2da52/att-verizon.jpg?auto=webp&width=1200

Source 25: https://blog.nuovoteam.com/what-is-push-to-talk-over-cellular-poc/

Source 26: https://www.intel.com/content/www/us/en/history/virtual-vault/articles/end-user-marketing-intel-inside.html

Categories
Report

(NASDAQ: GNPX) Profile

OUR NEW PROFILE IS:   (NASDAQ: GNPX)

________________________

GNPX HAS ALREADY RECEIVED FAST TRACK DESIGNATION FOR ACCLAIM 2

GENPREX ANNOUNCES U.S. PATENT FOR REQORSA™ IMMUNOGENE THERAPY IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS TO TREAT CANCERS

CHECK OUT THE INVESTOR PRESENTATION HERE

_________________________

Hello Everyone,

We have another exciting profile that we want you to look at for tomorrow’s session.

Rodney Varner, CEO of Austin-based biotech company Genprex, stands at the podium during the closing bell ceremony for the Nasdaq exchange in 2018 following the company's initial public offering of stock. [Photo courtesy Genprex]

Pull up GNPX right away and get it on your screen.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its unique, proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is then taken up by tumor cells that express proteins that are deficient. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In 2020, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for REQORSA for NSCLC in combination therapy with AstraZeneca’s Tagrisso® (osimertinib) for patients with EFGR mutations whose tumors progressed after treatment with Tagrisso. In 2021, the FDA granted Fast Track Designation for REQORSA for NSCLC in combination therapy with Merck & Co’s Keytruda® (pembrolizumab) for patients whose disease progressed after treatment with Keytruda.

https://platform.twitter.com/embed/Tweet.html?dnt=false&embedId=twitter-widget-0&features=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&frame=false&hideCard=false&hideThread=false&id=1627654588219236352&lang=en&origin=https%3A%2F%2Finsiderfinancial.com%2Fgnpx11%2F&sessionId=0887ee94258b228d19d1d8a368c4a550c3d20569&theme=light&widgetsVersion=aaf4084522e3a%3A1674595607486&width=550px

CATALYSTS

– Addressing unmet medical need in large markets through the buildout of a robust pipeline of new drug candidates and drug combinations.

– Leveraging a gene therapy platform; Genprex’s non-viral ONCOPREX® Nanoparticle Delivery System is designed to deliver a variety of therapeutic genes to fight multiple types of cancer.

– REQORSATM immunogene therapy, the first systemically delivered gene therapy used for cancer in humans, can be combined with top-selling cancer drugs and may improve their benefits.

– Genprex has demonstrated clinical achievement with REQORSA in two clinical trials, showing a favorable safety profile and evidence of efficacy in lung cancer.

– GPX-002, Genprex’s diabetes gene therapy, works to transform alpha cells in the pancreas into insulin producing beta-like cells. A Phase 1 clinical trial could be the first-ever gene therapy tested in humans for diabetes.

– Advancing novel gene therapies in diseases with large markets and unmet needs.

– Two NSCLC trials currently enrolling; both with FDA Fast Track Designations.

– World class academic partners.

TAKE A LOOK AT THE CHART.  SINCE EARLY JANUARY GNPX HAS BEEN ON THE MOVE AND IS LOOKING LIKE IT COULD RETEST 2023 HIGHS IF THE MARKETS COOPERATE.

 CLINICAL TRIALS

ONC-001

EVALUATING THE SAFETY OF REQORSA® IMMUNOGENE THERAPY AS A MONOTHERAPY (COMPLETED)

A Phase 1 dose escalation trial was conducted at The University of Texas MD Anderson Cancer Center evaluating the systemic, intravenous delivery of REQORSA® (TUSC2/FUS1) as a monotherapy in stage IV recurrent, metastatic lung cancer patients. The primary objective of this Phase 1 trial was to assess the toxicity of REQORSA administered systemically and intravenously, to determine the maximum tolerated dose, or MTD, and to determine a recommended Phase 2 dose of REQORSA alone.

THE FIRST SYSTEMICALLY DELIVERED GENE THERAPY USED FOR CANCER IN HUMANS

The study showed for the first time that a tumor suppressor gene can be delivered systemically, intravenously and selectively to a patient’s cancer cells using a systemic nanoparticle vector. Although this trial was not designed to show changes in outcomes, a halt in cancer growth was observed in a number of patients. REQORSA was well tolerated with tumor responses noted in lung primary and metastatic cancers in the liver, pancreas, and lymph nodes. In addition, pre- and post-treatment patient biopsies demonstrated that intravenous REQORSA selectively and preferentially targeted patients’ cancer cells.

Metabolic Tumor Response in a Metastatic Lung Cancer Subject

This subject survived after subsequent therapy more than seven years after the final treatment with REQORSA, to our knowledge, without evidence of cancer progression in the responding sites.ONC-002COMBINING REQORSA® IMMUNOGENE THERAPY WITH TARCEVA (ERLOTINIB)PHASE 1 PORTION COMPLETED; PHASE 2 PORTION NO LONGER ENROLLING DUE TO OUR CHANGE OF FOCUS TO CONDUCT ACCLAIM-1A Phase 1/2 clinical trial evaluated REQORSA® in combination with Tarceva® in stage IIIB/IV lung cancer patients without an activating EGFR mutation and in patients with an activating EGFR mutation whose cancer has progressed on Tarceva therapy.  Patients without the EGFR mutation represent the vast majority of lung cancer patients. However, such patients generally are not candidates for Tarceva therapy.In the Phase 2 trial combining REQORSA with Tarceva, subjects received REQORSA in combination with Tarceva every 21 days until the occurrence of progressive disease (PD), unacceptable toxicity, withdrawal of consent, or study treatment discontinuation for other reasons, whichever occurred first. We believe that the results from the Phase 2 trial are encouraging. Out of 10 patients, 9 had received 2 or more cycles and were therefore evaluable for response. Four patients had tumor regression. The median duration of response is three months. The disease control rate (CR+PR+SD > 8weeks) was 78%, which substantially exceeds the 7% response rate (with no CRs) and 58% disease control rate reported for the LUX-Lung 1 trial, a clinical trial of Gilotrif (afatinib) in a comparable group of patients.REQORSA + Tarceva Combination: Phase 2 data in subjects with or without EGFR mutationsACCLAIM-1 COMBINING REQORSA™ IMMUNOGENE THERAPY WITH TAGRISSO (OSIMERTINIB)Preliminary analysis of the interim data from the Phase 2 portion of our ONC-002 trial supported our belief that REQORSA™ may provide medical benefit in several subpopulations of NSCLC patients for which there is an unmet medical need, and may provide pathways for accelerated approval by the U.S. Food and Drug Administration, or FDA. Data from our clinical trials, along with our preclinical data, provided the basis for our application for a Fast Track Designation, which was granted by FDA on January 14, 2020.In granting our Fast Track Designation, the FDA found that REQORSA may provide a benefit over existing therapies for patients whose tumors progress on AstraZeneca’s Tagrisso. The FDA Fast Track Designation is for use of REQORSA in combination with TKI Tagrisso for the treatment of NSCLC patients with EGFR mutations whose tumors progressed after treatment with Tagrisso. We believe that the Fast Track Designation provides a clearly defined pathway toward FDA approval of the combination of REQORSA with Tagrisso.We initiated the Acclaim-1 clinical trial in June 2021, a Phase 1/2 clinical trial of REQORSA combined with Tagrisso. To learn more about Acclaim-1, please visit ClinicalTrials.gov.To learn more about scientific evidence and studies supporting REQORSA and the TUSC2 gene, please refer to our TUSC2 Bibliography page.ACCLAIM-2COMBINING REQORSA™ IMMUNOGENE THERAPY WITH KEYTRUDA (PEMBROLIZUMAB)Researchers at MD Anderson Cancer Center have conducted preclinical studies evaluating REQORSA™ in combination with anti-PD1 checkpoint inhibitors, including Merck’s Keytruda.Positive and encouraging data indicate that REQORSA is synergistic with immunotherapies.In April 2019, we reported that our collaborators at MD Anderson presented positive preclinical data for the combination of TUSC2 with pembrolizumab, demonstrating that TUSC2 combined with checkpoint blockade was more effective than checkpoint blockade alone in increasing the survival of mice with human immune cells, that had metastatic lung cancer.In November 2019, we reported that our collaborators at MD Anderson presented positive preclinical data for the combination of TUSC2, pembrolizumab and chemotherapy for the treatment of some of the most resistant metastatic lung cancers. This study found that the combination of TUSC2 increases the effectiveness of pembrolizumab and chemotherapy, and thus, may improve on first-line standard of care for lung cancer.In May 2020, we entered into a worldwide, exclusive license agreement with The Board of Regents of the University of Texas System on behalf of MD Anderson for the use of TUSC2 in combination with immunotherapies, including Keytruda, and also for the use of TUSC2 in a three-drug combination of TUSC2, immunotherapy and chemotherapy.In December 2021, we received Fast Track Designation from the FDA for use of REQORSA in combination with the checkpoint inhibitor Keytruda for the treatment of advanced NSCLC patients whose tumors progressed after treatment with Keytruda.In March 2022, we opened the Acclaim-2 clinical trial for patient enrollment, a Phase 1/2 clinical trial of REQORSA combined with Keytruda. To learn more about Acclaim-2, please visit ClinicalTrials.gov.To learn more about scientific evidence and studies supporting REQORSA and the TUSC2 gene, please refer to our TUSC2 Bibliography page.DIA-001STUDYING GPX-002 IN DIABETIC MICEResearchers at the University of Pittsburgh have conducted preclinical studies evaluating GPX-002 in diabetic mice models. In vivo mice studies have found that GPX-002 restored normal blood glucose levels for an extended period of time, typically around four months. The duration of restored blood glucose levels in mice could translate to decades in humans.These researchers are continuing to conduct preclinical studies in diabetic primates. Once sufficient preclinical data has been generated, we expect to begin a Phase 1 clinical trial in diabetic patients, which could be the first-ever gene therapy tested in humans for diabetes.To learn more about scientific evidence and studies supporting GPX-002 and the Pdx1/MafA genes, please refer to our Pdx1/MafA Bibliography page.ONCOLOGY COMBINATION TREATMENT APPROACHOur oncology program uses a modern combinational treatment approach to fight cancer, utilizing our lead drug candidate, REQORSA™ immunogene therapy and our unique, proprietary, non-viral ONCOPREX® nanoparticle delivery system combined with approved targeted therapies and immunotherapies. This enables us to offer hope to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them.ONCOLOGY COMBINATION TREATMENT APPROACHOur research indicates that when REQORSA, our lead drug candidate for non-small cell lung cancer (NSCLC), is combined with targeted therapies such as Tarceva (erlotinib) or Tagrisso (osimertinib) or with immunotherapies such as Opdivo (nivolumab) or Keytruda (pembrolizumab), REQORSA is synergistic with those drugs, meaning that the combination is more effective than either drug alone. We believe that by combining REQORSA with targeted therapies and immunotherapies, we can extend the benefit of these approved lung cancer drugs into the large majority of patients who do not now benefit from them, either because the patients’ tumors do not have the molecular profiles that indicate effectiveness of those drugs, or because the patients have developed resistance to those drugs after receiving them for some period of time.To learn more about our combination trials utilizing our oncology combination treatment approach, refer to our Pipeline and Clinical Trials pages.TARGETED THERAPIESTargeted therapies work by targeting the cancer or disease’s specific gene, protein or tissue that contributes to the disease while sparing normal tissue. Unfortunately, targeted therapies require patients to have an activating genetic mutation specific to the drug. In NSCLC, the vast majority of lung cancer patients do not have the genetic mutations that qualify them for targeted therapies, such as the EGFR or ALK gene. In addition, the few patients who do have the genetic mutation qualifying them to receive targeted therapies are likely to develop resistance to these drugs over time.In January 2020, we received a United States FDA Fast Track Designation for use of REQORSA in combination with EGFR inhibitor Tagrisso for the treatment of NSCLC patients with EFGR mutations whose tumors progressed after treatment with Tagrisso. The median length of time that patients are treated with Tagrisso before their tumors progress is approximately eighteen (18) months.IMMUNOTHERAPIESImmunotherapy is a type of treatment that helps the immune system fight disease. Biomarker testing can help determine if high levels of PD-1/PD-L1 proteins are detected in the patient, signifying that the body’s immune system is not working to fight cancer or disease as it should. These patients could qualify for approved immunotherapies, however, not all patients benefit from immunotherapies.Genprex is conducting preclinical studies to evaluate REQORSA in combination with checkpoint inhibitors. Preclinical data indicate that Genprex’s lead drug candidate is synergistic with checkpoint inhibitors, such as Merck’s Keytruda, meaning that the combination of drugs may be more effective than checkpoint inhibitors alone. Preclinical data also indicates that a three-drug combination of a checkpoint inhibitor, chemotherapy, and REQORSA may be more effective than the two-drug combination of a checkpoint inhibitor and chemotherapy.MARKET OPPORTUNITYAstraZeneca’s Tagrisso had more than $4 billion in worldwide gross sales in 2020, and Tagrisso is AstraZeneca’s highest grossing product. Given Genprex’s Fast Track Designation and Tagrisso’s status as the current standard of care in EGFR-mutated NSCLC, we have prioritized the clinical development of REQORSA in combination with Tagrisso. We believe this regulatory pathway positions us well in the $17.9 billion global lung cancer market, especially given the advantages of our Fast Track Designation status.Merck’s Keytruda generated more than $14 billion in worldwide sales in 2020, and Keytruda is Merck’s highest grossing product. Keytruda is the standard of care in non-EGFR mutated NSCLC. Genprex plans to initiate a Phase I/II clinical trial evaluating REQORSA in combination with pembrolizumab.PROGRAMSLUNG CANCERCANCERCancer is a complex disease that can start in any site in the body when a tissue grows out of control and inhibits the body’s normal functioning. At the cell level, cancer often involves the dysregulation of multiple genes and cellular pathways, leading to the cell’s inability to maintain proper cellular functions. Re-establishing or blocking these pathways can be done through many therapeutic approaches, including gene therapy. More general information about cancer can be found at The American Cancer Society.LUNG CANCERGenprex’s oncology program is focused on developing new treatments for cancer. Our initial therapeutic target is lung cancer, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).According to the World Health Organization in 2020, lung cancer was the leading cause of cancer deaths worldwide, causing more deaths than colorectal, breast, liver, or stomach cancers. In 2020, there were more than 2 million new lung cancer cases and 1.8 million deaths from lung cancer worldwide. In the United States, according to the American Cancer Society, it is estimated that in 2022 there will be more than 236,000 new cases of lung cancer and more than 130,000 deaths from this disease. NSCLC represents 84% of all lung cancers and the five-year survival rate for patients with NSCLC with distant spread is 7 percent. SCLC represents about 13% of lung cancer patients and the five-year survival rate for patients with SCLC with distant spread is 3 percent. With limited benefit from current therapies, we believe there is a significant unmet medical need for new treatments for NSCLC and SCLC in the United States and globally, and we believe REQORSA may be suitable for the majority of lung cancer patients.DIABETESDIABETESOur diabetes gene therapy candidate, GPX-002, is being developed for the treatment of diabetes.According to the U.S. Center for Disease Control, 37 million Americans, or approximately 11% of the population, have diabetes. It is also believed that more than 96 million Americans have prediabetes, which represents approximately 38% of the U.S. population. The prevalence of this chronic disease is continuing to rise.Chronic diabetes conditions include Type 1 diabetes and Type 2 diabetes, both of which lead to excess sugar in the blood and can cause serious health problems. Left untreated, high blood sugar levels can damage eyes, kidneys, nerves, and the heart, and can also lead to coma and death.

TECHNOLOGY

REQORSA® IMMUNOGENE THERAPY

THE FIRST SYSTEMICALLY DELIVERED GENE THERAPY USED FOR CANCER IN HUMANS

Our lead product candidate, REQORSA®  immunogene therapy (quaratusugene ozeplasmid) for non-small cell lung cancer (NSCLC), uses the company’s unique, proprietary ONCOPREX® Nanoparticle Delivery System, which we believe is the first systemic gene therapy delivery platform used for cancer in humans. In 2020, the FDA granted Fast Track Designation for REQORSA in combination with AstraZeneca’s Tagrisso® (osimertinib) in late-stage NSCLC patients with EFGR mutations whose tumors progressed after treatment with Tagrisso. In 2021, the FDA granted Fast Track Designation for REQORSA in combination with Merck & Co’s Keytruda® (pembrolizumab) in late-stage NSCLC patients whose disease progressed after treatment with Keytruda.

The active ingredient in our lead product candidate, REQORSA, is the TUSC2 gene, a tumor suppressor gene.

REQORSA consists of the TUSC2 gene encapsulated in a nanoparticle made from lipid molecules with a positive electrical charge. REQORSA is injected intravenously and can specifically target cancer cells, which generally have a negative electrical charge. Once REQORSA is taken up into a cancer cell, the TUSC2 gene is expressed into a protein that is capable of restoring certain defective functions arising in the cancer cell. REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for programmed cell death, or apoptosis, in cancer cells, and modulates the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance.

We believe that REQORSA, unlike other gene therapies, which either need to be delivered directly into tumors or require cells to be removed from the body, re-engineered and then reinserted into the body, is the first systemic gene therapy used for cancer in humans.

OVERCOMING DRUG RESISTANCE

REQORSA is a pan-kinase inhibitor shown to simultaneously inhibit the EGFR and AKT oncogenic kinase pathways in vitro and in vivo. Once the cancer cell takes up the nanoparticle containing TUSC2, it is reprogrammed to die. Resistance to targeted drugs and checkpoint inhibitors develop through activation of alternate bypass pathways. For example, when PD-1 is blocked, the TIM-3 checkpoint is up-regulated. We believe that REQORSA’s multimodal activity will block emerging bypass pathways, reducing the probability that drug resistance develops.

To learn more about scientific evidence and studies supporting REQORSA and the TUSC2 gene, please refer to our Clinical Trials and TUSC2 Bibliographypages.

GPX-002

DIABETES GENE THERAPY

GPX-002, a gene therapy for diabetes, is the most recent addition of our licensed technologies. GPX-002 was developed by researchers at the University of Pittsburgh. Diabetic mice studies have shown that GPX-002 restored normal blood glucose levels for an extended period of time, which could translate to decades in humans. This gene therapy could not only become a new treatment option for millions of diabetes patients who need insulin replacement therapy, but it holds the potential to provide long-term effectiveness, or may even be a cure, for diabetic patients.

The diabetes gene therapy, GPX-002, is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes to the pancreas. The genes express proteins that transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system.

Image source: Osipovich, Anna & Magnuson, Mark. (2018). Alpha to Beta Cell Reprogramming: Stepping toward a New Treatment for Diabetes. Cell Stem Cell. 22. 12-13. 10.1016/j.stem.2017.12.012.

Diabetic mice studies show that the gene therapy restored normal blood glucose levels for an extended period of time, typically around four months. The duration of restored blood glucose levels in mice could translate to decades in humans.

The diabetes gene therapy was developed by Dr. George Gittes, a researcher at the Rangos Research Center at UPMC Children’s Hospital of Pittsburgh, where preclinical research is ongoing. GPX-002 has been tested in vivo in mice and nonhuman primates. Once sufficient preclinical data has been generated, we expect to begin a Phase I clinical trial in diabetic patients, which could be the first-ever gene therapy tested in humans for diabetes.

To learn more about scientific evidence and studies supporting GPX-002 and the Pdx1/MafA genes, please refer to our Clinical Trials and Pdx1/MafA Bibliography pages.

ONCOPREX® NANOPARTICLE DELIVERY SYSTEM

THE FIRST SYSTEMIC GENE THERAPY DELIVERY PLATFORM USED IN HUMANS FOR CANCER

Our oncology drug development program utilizes our unique, proprietary non-viral ONCOPREX Nanoparticle Delivery System, which we believe is the first systemic gene therapy delivery platform used for cancer in humans. This platform, originally developed through collaborative research between the University of Texas MD Anderson Cancer Center and the National Institutes of Health, has been optimized to work with our initial product candidate, REQORSA® immunogene therapy.

DESIGNED TO DELIVER CANCER-FIGHTING GENES SYSTEMICALLY

The ONCOPREX platform has been designed and optimized to deliver cancer-fighting genes into the patient’s body systemically. Using this system, we encapsulate plasmids that express tumor suppressor genes within lipid nanoparticles and intravenously administer the encapsulated plasmids which are taken up by the tumor cells, after which the tumor suppressor genes express proteins that are missing or found in low quantities in the tumor cells. Our nanoparticles are non-immunogenic, allowing repetitive therapeutic dosing and have been clinically shown to deliver molecular kinase inhibitors effectively.

OPTIMIZED PARTICLE SIZE

Our systemic, nanoparticle, non-viral delivery system, which is being used in our clinical trials for the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), is designed to be small enough to cross tight barriers in the lungs but large enough to avoid accumulation in the liver, spleen and kidney. The nanoparticles have been shown to be taken up by tumor cells after REQORSA administration at up to 33 times the rate they are taken up by normal cells. The cationic charge of the lipid nanoparticles targets cancer cells, which facilitates endocytosis. Once inside the cancer cell, the TUSC2 gene activates signaling pathways that result in cell destruction or apoptosis.

ENHANCED SAFETY AND EFFICACY DESIGN

We have administered REQORSA to more than 50 patients in Phase 1 and 2 clinical trials using our systemic, proprietary, non-viral delivery system.

A Phase 1 clinical trial showed that systemic, intravenous therapy using the ONCOPREX Nanoparticle Delivery System was shown to selectively and preferentially target primary and metastatic tumor cells, resulting in clinically significant anticancer activity. The nanoparticles are non-immunogenic, allowing repetitive therapeutic dosing and providing extended half-life in the circulation.

Our earlier clinical trials have also shown that the ONCOPREX Nanoparticle Delivery System is well tolerated in humans and can safely deliver high therapeutic doses. We believe the ONC-001 clinical trial was the first systemic gene therapy clinical trial using a nanoparticle delivery system to deliver a tumor suppressor gene.

GENPREX RECEIVES SAFETY REVIEW COMMITTEE APPROVAL TO PROCEED TO FINAL COHORT IN ACCLAIM-1 PHASE 1 DOSE ESCALATION TRIAL OF REQORSA® IN COMBINATION WITH TAGRISSO® IN ADVANCED NON-SMALL CELL LUNG CANCER

Recommendation to Advance to Increased Dose in Third and Final Cohort of Phase 1 Portion of Trial Indicates Favorable Safety Profile of Novel Gene Therapy in Solid Tumor Cancer

AUSTIN, Texas — (December 14, 2022) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Safety Review Committee (SRC) has approved continuation to the third and final cohort in the dose escalation Phase 1 portion of the Acclaim-1 Phase 1/2 clinical trial of REQORSA® in combination with Tagrisso® (osimertinib) to treat late-stage non-small cell lung cancer (NSCLC). In 2020, the combination of REQORSA and osimertinib received U.S. Food and Drug Administration’s (FDA) Fast Track Designation for treatment of the Acclaim-1 patient population.

Acclaim-1 is an open-label, multi-center Phase 1/2 clinical trial evaluating the Company’s lead drug candidate, REQORSA Immunogene Therapy, in combination with Tagrisso (osimertinib) in patients with late-stage non-small cell lung cancer (NSCLC) whose disease progressed after treatment with Tagrisso.

The SRC is comprised of three physicians who are principal investigators in the trial. The SRC may recommend that the trial continues at the same dose or at a lower dose, that it escalates to a higher dose, or that the study be terminated altogether due to safety concerns.

“The SRC’s recommendation to increase the dosing of REQORSA is further confirmation of its favorable safety profile and it enables us to advance Acclaim-1 into the final cohort of the Phase 1 dose escalation portion of the study,” said Mark Berger, M.D., Chief Medical Officer of Genprex. “We look forward to completing enrollment of this final cohort in the first quarter of 2023.”

The Accaim-1 trial includes up to three sequential dose escalation cohorts that will treat study participants with REQORSA intravenously on Day 1 in addition to osimertinib 80 mg fixed dose oral daily tablet during 21-day treatment cycles until disease progression or unacceptable toxicity. The first group received REQORSA IV infusion at 0.06 mg/kg, the second group received 0.09 mg/kg, and the third group will receive 0.12 mg/kg.

Following successful completion of the Phase 1 dose escalation portion of the Acclaim-1 study, the Company will advance into the dose expansion portion of the study, which will evaluate  the toxicity profile of REQORSA in combination with Tagrisso in patients with different eligibility criteria, and will also evaluate efficacy and other endpoints.

“The principal advantage of adding the dose expansion portion to Acclaim-1 is to gain efficacy data earlier than we would otherwise have received it from the Phase 2 portion of the study. We also will receive this data in the two distinct patient populations represented by the two expansion cohorts, which we believe will further increase the likelihood of a successful Phase 2 trial,” added Dr. Berger.

GENPREX STRENGTHENS DIABETES GENE THERAPY PROGRAM WITH LICENSE OF ADDITIONAL TECHNOLOGY FROM UNIVERSITY OF PITTSBURGH

DECEMBER 15, 2022

Technology for modulating autoimmunity expands intellectual property portfolio 

AUSTIN, Texas — (December 15, 2022) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement (the Agreement) with

the University of Pittsburgh, granting Genprex a worldwide, exclusive license to certain patent applications and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to modulating autoimmunity in Type 1 diabetes by using gene therapy. The preclinical technology transforms macrophages enabling them to reduce autoimmune activity in Type 1 diabetes and could be complementary to the Company’s existing diabetes technology.

“Gaining exclusive access to technology that modulates the immune system by transforming macrophages could prove to be significant to our broader research partnership with the laboratory of George Gittes, MD, Professor of Surgery and Pediatrics and Chief of the Division of Pediatric Surgery at the University of Pittsburgh School of Medicine,” said Mark Berger, MD, Chief Medical Officer of Genprex. “We are making significant strides in our program with Dr. Gittes’s innovative approach to treating diabetes by the transformation of alpha cells into beta-like cells and are excited to add to our arsenal this additional technology also out of Dr. Gittes’s lab, in collaboration with the laboratory of Dr. Xangwei Xiao, Assistant Professor of Surgery, also in the Division of Pediatric Surgery at the University of Pittsburgh’s School of Medicine. Not only could this new approach be used to reduce autoimmune activity in Type 1 diabetes by modulating the immune system but potentially it could also work in conjunction with the technology we have licensed previously.”

“With diabetes reaching epidemic proportions around the world, the work Dr. Gittes is pursuing in diabetes is absolutely critical. In the U.S. alone, there are more than 37 million people with diabetes (approximately 1.9 million of whom have Type 1 diabetes) and another approximately 96 million Americans who are pre-diabetic, or have abnormally elevated blood sugar levels. The opportunity to change the course of this disease with gene therapy is extremely compelling, and increasing our exclusive access to intellectual property could prove to be pivotal to our pathway forward,” said Rodney Varner, President and Chief Executive Officer of Genprex.

The Company signed an exclusive license agreement with the University of Pittsburgh in 2020. The gene therapy approach under the original license is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, these genes express proteins that transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system. In Type 2 diabetes, where autoimmunity is not at play, it is believed that exhausted beta cells will be rejuvenated and replenished.

This gene therapy approach was developed by Dr. Gittes. His preclinical research in this area has been published in peer-reviewed scientific publications, and he is the recipient of several research grants, including a $2.59 million grant awarded by the National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases. Earlier studies in diabetic mouse models showed that the gene therapy restored normal blood glucose levels for an extended period of time, typically around four months. It is believed that the duration of restored blood glucose levels in mice could translate to decades in humans. Preliminary data from a more recent study in a non-human primate model of Type 1 diabetes also have been promising. Data from this study are expected to be presented at a scientific meeting during the first quarter of 2023.

NEWS

GENPREX SIGNS EXCLUSIVE LICENSE TO ADDITIONAL DIABETES TECHNOLOGY WITH THE UNIVERSITY OF PITTSBURGH

JANUARY 5, 2023

Technologies Licensed from University of Pittsburgh May Have the Potential to Provide Long-Term Efficacy and to Change the Course of this Disease for the Millions of Patients Around the World with Type 1 or Type 2 Diabetes

Read More


GENPREX ANNOUNCES SELECTION OF PRECLINICAL DATA FOR ORAL PRESENTATION AT 16TH INTERNATIONAL CONFERENCE ON ADVANCED TECHNOLOGIES & TREATMENTS FOR DIABETES 

JANUARY 4, 2023

Exciting Data from University of Pittsburgh Researchers in Non Human Primates that Underpins Genprex’s Gene Therapy Program in Diabetes to be Showcased

Read More


GENPREX STRENGTHENS DIABETES GENE THERAPY PROGRAM WITH LICENSE OF ADDITIONAL TECHNOLOGY FROM UNIVERSITY OF PITTSBURGH

DECEMBER 15, 2022

Technology for modulating autoimmunity expands intellectual property portfolio

Read More


GENPREX RECEIVES SAFETY REVIEW COMMITTEE APPROVAL TO PROCEED TO FINAL COHORT IN ACCLAIM-1 PHASE 1 DOSE ESCALATION TRIAL OF REQORSA® IN COMBINATION WITH TAGRISSO® IN ADVANCED NON-SMALL CELL LUNG CANCER

DECEMBER 14, 2022

Recommendation to Advance to Increased Dose in Third and Final Cohort of Phase 1 Portion of Trial Indicates Favorable Safety Profile of Novel Gene Therapy in Solid Tumor Cancer

Read More


GENPREX TO PRESENT AT UPCOMING DECEMBER INVESTOR CONFERENCE

DECEMBER 2, 2022

Corporate Presentation to Highlight Company’s Gene Therapies for Cancer and Diabetes

Read More


GENPREX TO PRESENT AT UPCOMING OCTOBER INVESTOR AND INDUSTRY CONFERENCES 

OCTOBER 7, 2022

Corporate and Clinical Presentations to Highlight Company’s Gene Therapies for Cancer and Diabetes

Read More


GENPREX TO PRESENT AT UPCOMING SEPTEMBER INVESTOR CONFERENCE  

SEPTEMBER 8, 2022

Corporate Presentation to Highlight Company’s Gene Therapies for Cancer and Diabetes

Read More


GENPREX ANNOUNCES U.S. PATENT FOR REQORSA™ IMMUNOGENE THERAPY IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS TO TREAT CANCERS

AUGUST 16, 2022

Intellectual Property Protection for Therapeutic Combination in Acclaim-2 Phase 1/2 Clinical Trial

Read More


GENPREX ANNOUNCES SAFETY REVIEW COMMITTEE APPROVES DOSE ESCALATION IN ACCLAIM-1 PHASE 1/2  TRIAL OF REQORSA™ IN COMBINATION WITH TAGRISSO® IN NON-SMALL CELL LUNG CANCER

AUGUST 15, 2022

Recommends Advancing Acclaim-1 to Increased Dose in Second Cohort of Phase 1 Portion of Trial

Read More


GENPREX TO PARTICIPATE IN NEXT GENERATION LIPID-BASED NANOPARTICLES DELIVERY SUMMIT

JULY 13, 2022

Company Manufacturing Leads Selected as Thought Leaders to Discuss Advances in Lipid Nanoparticle Delivery Systems

Read More


MANAGEMENT

Check out the management team here: https://www.genprex.com/about/company-management/

Sincerely,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY A THIRD PARTY, LEGENDS MEDIA  FOR A ONE DAY GNPX AWARENESS CAMPAIGN. WE HAVE PREVIOUSLY BEEN COMPENSATED FORTY THOUSAND USD IN TOTAL TO COVER GNPX. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS, LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Categories
Report

NEW NASDAQ PROFILE: Avalon Global Care (Nasdaq: ALBT)

logo

OUR NEW PROFILE IS:    (NASDAQ: ALBT)

AVALON INSIDERS CURRENTLY OWN OVER 33% OF AVAILABLE SHARES

AVALON JUST ANNOUNCED A NEW RESEARCH STUDY APPLYING ARTIFICIAL INTELLIGENCE (AI) ENHANCED PROTEIN DESIGN “QTY CODE” TECHNOLOGY – WHICH IS EXPECTED TO ACCELERATE THE DEVELOPMENT OF THERAPEUTIC MONOCLONAL ANTIBODIES TO TREAT CANCER

AVALON GLOBOCARE SIGNS DEFINITIVE AGREEMENT FOR TRANSFORMATIONAL ACQUISITION OF LEADING LABORATORY WITH 2021 UNAUDITED REVENUE IN EXCESS OF $25 MILLION

______________

CHECK OUT THE INVESTOR PRESENTATION HERE

_______________________________________

Hello Everyone,

We have another low priced Nasdaq company that we want you to have on your radar for today’s session.

Pull up ALBT immediately.

There are several key catalysts in play worth looking at as this company kicks off 2023.

     Movement and Volatility:

Avalon GloboCare Corp. (Nasdaq: ALBT) made a 97.05% move in November when it started from its $.38 intraday low on 11/01/2022 and reached $0.7488 by 11/08/2022 before pulling back to its current level according to Barchart.com’s pricing history. (22)

     INSIDER OWNERSHIP:

Over the past 12 months, insiders at Avalon GloboCare Corp. (ALBT) have bought more shares than they have sold. Wenzhao Lu, a Director in the company, was the latest insider to buy. Acquiring over 10,000,000 shares in July and buying more than 448,000 shares at $.78 on August 5, 2022, he has been adding at a significant rate according to stock research platform WallStreetZen.(24)

     CRACKING THE CANCER CODE:

Avalon recently announced a new research study applying artificial intelligence (AI) enhanced protein design “QTY Code” technology – which is expected to accelerate the development of therapeutic monoclonal antibodies to treat cancer. (12)

     PATENTS:

Avalon has jointly filed 16 patent applications, co-invented with key strategic partners, including a top-5 U.S. university, a leading education and research center in Europe, as well as a premier multi-national developer of cellular therapies in the field of oncology.(13)

     REMARKABLE SECTOR GROWTH:

Based on worldwide sales forecasts from Evaluate Pharma, including both approved drugs and ones forecast to be approved, it is expected that conventional drug sales will grow at a compound annual growth rate (CAGR) of 6% from 2021 to 2026 and biologic sales excluding cell and gene therapies are forecast to grow from $415 billion to $541 billion, a CAGR of 5%. Cell and gene therapies, in comparison, are expected to grow from $4 billion a year in sales to over $45 billion over that same period, a significantly higher CAGR of 63%.(39)

Avalon GloboCare Corp. (Nasdaq: ALBT) is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as cell therapy related companion diagnostics. (31)

Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets.(31)

Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics.(31)

T-Cells are  your immune system’s frontline soldiers in the fight against common infections and everyday maladies.

When you’re stuck at home on bedrest, your T-Cells are hard at work getting you back into healthy shape.

Sometimes though, they’re no match for deadly conditions like blood cancer (more specifically leukemia and non-Hodgkins Lymphoma).

That’s where Chimeric Antigen Receptor T-Cell (or “CAR-T”) therapy comes in.4

CAR-T therapy works by extracting your body’s own T-Cells, then genetically modifying them with a receptor that directly attacks specific types of cancers. The cells are then grown and multiplied in the lab before being re-introduced to the body, where they can hunt down cancerous elements in the body’s bloodstream.

That’s why the experts refer to CAR-T therapy as a potential “Living Cure” for some of the world’s deadliest diseases.

Even in its earliest forms as a treatment for blood cancer, this relatively non-invasive treatment leads to lasting remission in no less than 30-40% of patients.

But one company could potentially drive that success rate much higher …

Avalon is a clinical-stage, vertically integrated, leading “CellTech” bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well related diagnostics and therapeutics.

The Company also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets.

Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, the Company is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and other related vaccine and therapeutics.

Their core focus at the moment is their 3rd Generation CAR-T therapy that can potentially be useful in the treatment of cancer and other life-threatening diseases along with their FLASH-CAR technology and stem cell derived Exosome technology called ACTEX. ACTEX can be used to treat a wide variety of conditions, from neurodegenerative disorders to immune health, orthopedic applications, wound management and even weight management.2

Avalon GloboCare successfully filed for a $50 Million shelf offering (S3) in January of 2019, and was also staked a $20 Million credit facility from Chairman Daniel Lu.

That same Daniel Lu also happens to be chairman of the Lu DaoPei hospital group, China’s largest hematology and CAR-T treatment center.3

Those types of connections are key to Avalon GloboCare’s vertical integration:

This kind of integration is a tremendous advantage for companies working in the clinical stage of the process, because it gives Avalon GloboCare a real-world path to market (and to potential revenues) without the imminent need to involve third parties or secure new funding.

That means the company has a direct pipeline that can take compelling research and new ideas, rapidly transform them into a marketable product, and then potentially fast-track the testing process.

Their lead CAR-T candidate, AVA-001, has already completed a pilot first-in-human trial in patients with B-cell acute lymphoblastic leukemia with a stated remission rate far higher than the industry standard.2 Avalon is currently expanding patient recruitment and indication.

Avalon recently announced a new research study applying artificial intelligence (AI) enhanced protein design “QTY Code” technology. The method is expected to accelerate the development of therapeutic monoclonal antibodies to treat cancer. (12)

The research demonstrates a novel method for quickly predicting the design of so-called “water-loving” or hydrophilic variant structures of the 14 glucose transport membrane proteins in cells, which allows researchers to study the proteins more easily in water. Glucose transport membrane proteins are deregulated in many tumor types and are a potentially important target for cancer therapy. (12)

The “QTY Code” breakthrough technology, developed by Avalon and the laboratory of Dr. Shuguang Zhang, Ph.D. MIT’s Media Lab in Boston, MA, is a protein-design platform that can turn water-insoluble transmembrane receptor proteins into water-soluble proteins, enabling their use in many clinical applications, including drug development. (12)

A team of scientists led by Dr. Zhang applied the QTY code to the 14 glucose transport membrane proteins that transport sugar to cells. They used Google’s AlphaFold2, a DeepMind AI program, which can accurately and quickly predict how proteins fold. Dr. Zhang and his team used the QTY code with the open-source AlphaFold2 to predict the structures of these proteins in both their natural hydrophobic shapes and their QTY-code altered water-soluble shapes. (12)

Recently, Avalon jointly filed 16 patent applications, and co-invented with key strategic partners, including a top-5 U.S. university, a leading education and research center in Europe, as well as a premier multi-national developer of cellular therapies in the field of oncology. Patents were filed with the U.S. Patent and Trademark Office (USPTO), the China National Intellectual Property Administration (CNIPA), and under the Patent Cooperation Treaty (PCT) covering 36 countries.

The new intellectual property covers three core patent families:

Engineering and bio-manufacturing of novel CAR T-cells related to the mRNA-based Flash-CARTM cellular therapy platform. This technology has been applied to Avalon’s AVA-011 CAR-T cell therapy candidate, which is currently at the process development stage to generate cGMP-grade CAR-T cells for upcoming first-in-human clinical trials.

Soluble, antibody-like cytokine/chemokine decoy receptors derived from the QTY protein design, with potential applications including mitigation of the “cytokine storm” associated with COVID-19 and cellular immunotherapy delivery, as well as broadening the range of therapeutic targets addressable by CAR T-cell therapies.

Novel S-layer coated emulsome technology (SLET)-derived fusion proteins intended for mucosal vaccine development, which are designed to trigger robust protective immune responses at the predominant sites of pathogen infection. The SLET platform provides a “molecular GPS system” to guide the trafficking and delivery of a payload to a targeted destination in the body.

WHY HAVE AVALON GLOBOCARE CORP. (NASDAQ: ALBT) INSIDERS BEEN BUYING MORE THAN THEY ARE SELLING… (24)

Over the past 12 months, insiders at Avalon GloboCare Corp. (ALBT) have bought more shares than they have sold. (24)

Chart Source (33)

Wenzhao Lu, a Director in the company, was the latest insider to acquire shares of Avalon GloboCare Corp. Acquiring well over 10,000,000 shares in July at $.65 and more than 448,000 shares at $.78 on August 5, 2022, according to stock research platform WallStreetZen.(24)

As of 12/5/22, Avalon GloboCare Corp. (Nasdaq: ALBT) company insiders still own over 33% of the company according to Finviz.com.(15)

AVALON GLOBOCARE CORP. (NASDAQ: ALBT) IS HEADQUARTERED IN ONE OF THE COUNTRY’S HOTTEST BREEDING GROUNDS FOR FOR SUCCESSFUL BIOTECH’S,

Image Source (36)

Avalon GloboCare Corp. (Nasdaq: ALBT) is headquartered in Freehold, New Jersey.

New Jersey’s biotechnology cluster has grown from a mere 30 companies in the early 1990s to approximately 3,200 establishments in the state today, with 46 of those firms responsible for a staggering 70 new FDA drug approvals between 2020 and 2021, according to the trade association BioNJ.(36)

And several sources indicate that despite recent IPO and capital market challenges, the biotech cluster’s ascension continues.(36)

Debbie Hart, president and CEO of BioNJ, says of the overall US/global biotech community: “The science is advancing by leaps and bounds, and it’s creating lots of opportunities, new companies, and new advances in therapies and treatments.”(36)

“When you look at what happened during the global pandemic – how the industry can really save the world – [it’s] not an understatement. It just speaks to ability and the science.”(36)

New Jersey’s specific biotech juggernaut partly stems from a constellation of cutting-edge advances in cell and gene therapy operating in tandem with a Garden State life sciences ecosystem replete with contract manufacturing and clinical research organizations, as well as specialized accountants, attorneys and other professionals who serve the industry.(36)

Such a network is particularly important for the biotechnology community given the challenges it faces.(36)

Dean J. Paranicas, president and CEO of the HealthCare Institute of New Jersey (HINJ), details the overall “high risk profile” for the biopharmaceutical industry: “There’s that challenge of having enough capital to develop your product, being able to get it through the regulatory cycle, and then commercializing [it] and getting it into the marketplace.”(36)

Paranicas additionally explains that New Jersey firms have beneficial opportunities to coordinate with the state’s research institutions as well as with more established companies located here.(36)

Also helping to lubricate the state’s growing industry is New Jersey’s proximity to Wall Street and, separately, a time-zone advantage, which facilitates business communication with locales as diverse as, say, California and the United Kingdom.(36)

AVALON GLOBOCARE CORP. (NASDAQ: ALBT) RECENTLY RECEIVED A NOTICE OF ALLOWANCE FROM THE US PATENT OFFICE.

Image Source (30)

Jointly with MIT, Avalon GloboCare Corp. (Nasdaq: ALBT) also submitted a new U.S. patent application for QTY Glucose Transporters.(35)

Avalon GloboCare Corp. (Nasdaq: ALBT) recently received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) related to its QTY fusion water-soluble receptor protein platform. The patent was jointly filed with Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT) and covers seven claims related to the technology.(35)

The Company also submitted a new patent application to the USPTO related to its QTY glucose transporter technology. This patent application was also jointly filed with Dr. Shuguang Zhang of MIT. QTY glucose transporters are deregulated in many tumor types and are potentially important targets for cancer therapy.(35)

The “QTY Code,” is a breakthrough technology that can turn difficult to work with water-insoluble transmembrane receptor proteins into water-soluble proteins, enabling their potential use in many clinical applications, including drug development.(35)

Avalon’s proprietary AVA-Trap™ technology utilizes the artificial intelligence (AI) enhanced QTY Code technology to turn receptor molecules into antibody-like decoy receptors that are able to mop up cytokines and chemokines, which are excessively produced during pathological conditions, such as CV-19 and cancer metastasis.(35)

“We continue to strengthen our IP portfolio as we believe our novel QTY code protein design technology holds great potential for biotechnology applications and could generate significant clinical advancements in cellular immunotherapy and immune-oncology,”

David Jin, M.D., Ph.D.

President and Chief Executive Officer of Avalon. (35)

“Our AI-enhanced protein design QTY Code technology co-developed with MIT’s Dr. Zhang is a novel platform that produces water-soluble proteins for a wide spectrum of biomedical applications including the design and construction of novel targets for application in cellular immunotherapy.”(35)

“We are also pleased to submit a new patent application to the USPTO related to QTY glucose transporters, which are important cancer therapy targets. We believe using the QTY technology will accelerate our understanding of these proteins and the development of antibodies against them to treat cancer,”

Dr. Jin.(35)

CORE PRODUCTS

Avalon achieves and fosters seamless integration of unique verticals to bridge and accelerate innovative research, bio-process development, clinical programs and product commercialization.

Avalon’s upstream innovative research includes: 

  • Novel therapeutic and diagnostic targets development utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT)
  • Co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK and other immune effector cell therapeutic modalities with Arbele Corp.

Avalon’s downstream medical team and facility consists of top-rated affiliated hospital network and experts specialized in hematology, oncology, cellular immunotherapy, hematopoietic stem/progenitor cell transplant, as well as regenerative therapeutics.

AVALON GLOBOCARE SIGNS DEFINITIVE AGREEMENT FOR TRANSFORMATIONAL ACQUISITION OF LEADING LABORATORY WITH 2021 UNAUDITED REVENUE IN EXCESS OF $25 MILLION

Company to acquire a majority interest in Laboratory Services MSO, LLC, a leading reference laboratory with 2021 unaudited revenue in excess of $25 million, net income in excess of $10 million and over 600,000 tests completed since inception

Cash portion to be financed with a private placement of $15 million of Avalon preferred stock, convertible at a floor of $1.00 per share, with leak-out provisions, no warrants and a 9-month lock up

Company to Begin Trading under New Symbol “ALBT” on November 10, 2022 

FREEHOLD, N.J., Nov. 08, 2022 (GLOBE NEWSWIRE) — Avalon GloboCare Corp. (“Avalon” or the “Company”)(NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today announced that it has signed a definitive acquisition agreement (the “Acquisition Agreement”) to acquire a 60% interest in Laboratory Services MSO, LLC, a premier reference laboratory. In connection with the transaction, and to reflect the expanded focus on lab testing and services, Avalon will be changing its ticker symbol from “AVCO” to “ALBT.” Shares of Avalon’s common stock will begin trading under the new ticker symbol “ALBT” on the Nasdaq Capital Market on Thursday, November 10, 2022. Until such time, Avalon’s common stock will continue to trade under the symbol “AVCO.”

Headquartered in Costa Mesa California, Laboratory Services provides a broad portfolio of diagnostic tests including drug testing, toxicology, and a broad array of test services, from general bloodwork to anatomic pathology, and urine toxicology. Specific capabilities include STAT blood testing, qualitative drug screening, genetic testing, urinary testing, sexually transmitted disease testing and more. Laboratory Services has developed a premier reputation for customer service and fast turnaround times in the industry. Laboratory Services has completed over 450,000 tests since inception, operates with 2021 unaudited annual revenue in excess of $25 million and has two locations in California.

Total consideration for the acquisition will be $31 million, consisting of (i) $15 million in cash, (ii) $15 million in shares of the Company’s Series B preferred stock and (iii) $1,000,000 payable on the first anniversary of the closing date. The preferred shares will be restricted from conversion for 12 months and thereafter will have leak-out provisions restricting conversion to only 10% of total holdings.

The Company paid a $5 million refundable cash advance in connection with the signing of the definitive agreement. Additionally, the seller will have an earnout tied to 2022 and 2023 positive cash flow targets of up to $10 million, payable in a combination of cash and shares of the Company’s common stock. At closing of the transaction, Sarah Cox, the Co-founder and CEO of Laboratory Services, will become Chief Operating Officer of the Company and will join the Company’s Board of Directors.

The closing of the transactions contemplated by the Agreement is subject to customary conditions to closing, including completion of financing for the remainder of the cash purchase price. The transaction is expected to close in 30 days, subject to a 90 day right of extension by the Company.

In connection with the transaction, the Company completed a private placement of $5 million in shares of the Company’s Series A preferred stock, which shares are convertible into shares of the Company’s common stock at the greater of $1.00 or 90% of the closing price of the Company’s common stock on the Nasdaq Stock Market on the day prior to conversion. The Company intends to raise an additional $10 million to finance the remaining cash purchase price under the same terms. The holders of the Series A preferred stock will be restricted from selling the shares of common stock issuable upon conversion of the Series A preferred stock for a period of 9 months and will be limited to selling no more than 10% of their shares of common stock in any calendar month. In connection with the acquisition, the Company will be issuing to the seller $15 million in shares of the Company’s Series B preferred stock, which shares will be convertible into shares of the Company’s common stock at a conversion price of $0.575 per share. The holders of the Series B preferred stock will be restricted from selling the shares of common stock issuable upon conversion of the Series B preferred stock for a period of 12 months from closing and will be limited to selling no more than 10% of their shares of common stock in any calendar month.

David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon, commented, “This is a transformative acquisition for Avalon as it brings significant revenue and positive cash flow and is expected to be highly accretive to earnings while adding strong clinical synergies to the existing Avalon portfolio. Laboratory Services has an impressive history of growth and is an established leader within the highly fragmented market for lab testing and services. Laboratory Services’ diagnostic business is highly synergistic with our existing precision companion diagnostic business and cellular technology platforms.”

“We are delighted to welcome Sarah Cox, Co-founder and CEO of Laboratory Services, and the entire Laboratory Services team to Avalon. Sarah and her team have a proven track record and tremendous reputation within the industry,” concluded Dr. Jin.

Sarah Cox, Co-Founder and CEO of Laboratory Services, further noted, “We could not be more excited to join forces with Avalon, as we share a common culture and commitment to putting the patient’s needs first. We have become a one stop shop for most clinical testing and each client is provided white glove treatment. We believe that the combination of our established infrastructure with Avalon’s resources, as well as cutting edge diagnostic and immune-therapy platform, is expected to establish Avalon as a formidable force in this rapidly growing industry.”

A more complete description of the terms of and conditions of the proposed transaction, conditions to closing and related matters will be included in a Current Report on Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission (“SEC”), which report will be available at the SEC’s website at www.sec.gov.

The securities described above were and will be offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the “Act”), and have not been and will not be registered under the Act, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Advisors

Revere Securities LLC is acting as an advisor to Avalon in the transaction. Lowenstein Sandler LLP is acting as legal counsel to Avalon in the transaction. Blythe Global LLC is acting as accounting advisor.

AVALON GLOBOCARE RECEIVES ALLOWANCE FOR JOINT U.S. PATENT

JOINTLY WITH MIT, THE COMPANY ALSO SUBMITTED A NEW U.S. PATENT APPLICATION FOR QTY GLUCOSE TRANSPORTERS

FREEHOLD, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) — Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today provided an update regarding the Company’s intellectual property portfolio featuring its QTY protein code technology.

The Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) related to its QTY fusion water-soluble receptor protein platform. The patent was jointly filed with Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT) and covers seven claims related to the technology.

The Company also submitted a new patent application to the USPTO related to its QTY glucose transporter technology. This patent application was also jointly filed with Dr. Shuguang Zhang of MIT. QTY glucose transporters are deregulated in many tumor types and are potentially important targets for cancer therapy.

The “QTY Code,” is a breakthrough technology that can turn difficult to work with water-insoluble transmembrane receptor proteins into water-soluble proteins, enabling their potential use in many clinical applications, including drug development.

Avalon’s proprietary AVA-Trap™ technology utilizes the artificial intelligence (AI) enhanced QTY Code technology to turn receptor molecules into antibody-like decoy receptors that are able to mop up cytokines and chemokines, which are excessively produced during pathological conditions, such as COVID-19 and cancer metastasis.

“We continue to strengthen our IP portfolio as we believe our novel QTY code protein design technology holds great potential for biotechnology applications and could generate significant clinical advancements in cellular immunotherapy and immune-oncology,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. “Our AI-enhanced protein design QTY Code technology co-developed with MIT’s Dr. Zhang is a novel platform that produces water-soluble proteins for a wide spectrum of biomedical applications including the design and construction of novel targets for application in cellular immunotherapy.”

“We are also pleased to submit a new patent application to the USPTO related to QTY glucose transporters, which are important cancer therapy targets. We believe using the QTY technology will accelerate our understanding of these proteins and the development of antibodies against them to treat cancer,” said Dr. Jin.

_____

AVALON GLOBOCARE (AVCO) – INVESTOR FORUM AT THE WORLD STEM CELL SUMMIT

______

AVCO NEWS

AVALON GLOBOCARE ANNOUNCES $4 MILLION PRIVATE PLACEMENT OF PREFERRED STOCK WITH THE COMPANY’S CHAIRMAN WHICH CONVERTS AT A SIGNIFICANT PREMIUM TO MARKET; PROCEEDS TO SUPPORT ACQUISITION OF LABORATORY SERVICES 

Dec 14, 2022

AVALON GLOBOCARE CONTINUES ITS U.S. CENTRIC STRATEGY WITH A NEW PROPOSED BOARD COMPOSITION IN PREPARATION FOR ACQUISITION OF LABORATORY SERVICES MSO, LLC 

Dec 12, 2022

AVALON GLOBOCARE ANNOUNCES NASDAQ TICKER SYMBOL CHANGE FROM “AVCO” TO “ALBT” 

Nov 9, 2022

AVALON GLOBOCARE SIGNS DEFINITIVE AGREEMENT FOR TRANSFORMATIONAL ACQUISITION OF LEADING LABORATORY WITH 2021 UNAUDITED REVENUE IN EXCESS OF $25 MILLION 

Nov 8, 2022

AVALON GLOBOCARE TO PRESENT AT THE LD MICRO MAIN EVENT XV ON OCTOBER 26TH 

Oct 19, 2022

AVALON GLOBOCARE RECEIVES ALLOWANCE FOR JOINT U.S. PATENT 

Sep 29, 2022

AVALON GLOBOCARE ANNOUNCES NEW STUDY FEATURING AI-ENHANCED PROTEIN DESIGN TECHNOLOGY TARGETING GLUCOSE TRANSPORTER AGAINST CANCER 

Jun 30, 2022

AVALON GLOBOCARE TO PRESENT AT THE JEFFERIES 2022 HEALTHCARE CONFERENCE 

May 25, 2022

AVALON GLOBOCARE SIGNS MOU TO FORM STRATEGIC PARTNERSHIP WITH LU DAOPEI HEMATOLOGY INSTITUTE TO DEVELOP PRECISION COMPANION DIAGNOSTICS FOR CELLULAR THERAPY 

May 18, 2022

AVALON GLOBOCARE EXPANDS IP PORTFOLIO; FILES 16 NEW PATENT APPLICATIONS 

Apr 27, 2022

______________________________

AVCO MANAGEMENT TEAM

DAVID JIN

Chief Executive Officer, President and Director

Dr. David Jin, MD, PhD, a director and Chief Executive Officer of the Company and AHS. From 2009 to 2016, Dr. Jin has served as the Chief Medical Officer of BioTime, Inc. (NYSE MKT: BTX), a clinical stage regenerative medicine company with a focus on pluripotent stem cell technology. Dr. Jin also acts as a senior translational clinician-scientist at the Howard Hughes Medical Institute and the Ansary Stem Cell Center at Weill Cornell Medical College of Cornell University. Prior to his current endeavors, Dr. Jin was Chief Consultant/Advisor for various biotech/pharmaceutical companies regarding hematology, oncology, immunotherapy and stem cell-based technology development. Dr. Jin has been Principle Investigator in more than 15 pre-clinical and clinical trials, as well as author/co-author of over 80 peer-reviewed scientific abstracts, articles, reviews, and book chapters. Dr. Jin studied medicine at SUNY Downstate College of Medicine in Brooklyn, NY. He received his clinical training and subsequent faculty tenure at the New York-Presbyterian Hospital (the teaching hospital for both Cornell and Columbia Universities) in the areas of internal medicine, hematology, and clinical oncology. Dr. Jin was honored as Top Chief Medical Officer by ExecRank in 2012, as well as recognized as Leading Physicians of the World in 2015.

MENG LI

Chief Operating Officer, Secretary and Director

Ms. Li served on the Company’s board from October 2017 through July 2018 and was re-appointed in February 2019. Ms. Li has over 15 years of executive experience in international marketing, branding, communications, and media investment consultancy. Ms. Li served as Managing Director at Maxus/GroupM (a WPP Group company) where she was responsible for business P&L and corporate management from 2006 to 2015. Prior to joining Maxus/Group M, Ms. Li worked for Zenith Media (a Publicis Group company) from 2000 to 2006 as Senior Manager. Ms. Li received a Bachelor of Arts in International Economic Law from Dalian Maritime University in China.

LUISA INGARGIOLA

Chief Financial Officer

Luisa Ingargiola has almost 20 years of experience in public company finance, compliance and capital markets oversight. She currently serves as Audit Chair of FTE Networks (FTNW) and Audit Chair of Electra Mecchanica (ECCTF). She has held various positions as Chief Financial Officer or Audit Chair with several public companies and has helped manage over $100 Million in financing.  Ms. Ingargiola has helped guide the uplist of several OTC companies to NASDAQ or the NYSE.   She graduated from Boston University with a Bachelor Degree in Business Administration and received her MBA in Health Administration from the University of South Florida.

SINCERELY,

DISCLAIMER

THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.

OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY A THIRD PARTY, LIFEWATER MEDIA  FOR A ONE DAY ALBT AWARENESS CAMPAIGN. WE HAVE PREVIOUSLY BEEN COMPENSATED A TOTAL OF FOURTEEN THOUSAND DOLLARS TO COVER ALBT. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS, LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. DEDICATED INVESTORS LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.

Source List

Source 1: https://www.globenewswire.com/news-release/2021/12/17/2354510/0/en/Cancer-Drugs-Market-Size-Worth-Around-US-272-Billion-by-2030.html

Source 2: https://www.youtube.com/watch?v=K2ZnjL0lOM8

Source 3: https://www.youtube.com/watch?v=4zDPUHxzajs

Source 4: https://www.lls.org/sites/default/files/National/USA/Pdf/LLS-CAR-T-cell-Therapy-Timeline.pdf

Source 5: http://www.avalon-globocare.com/

Source 6: https://simplywall.st/stocks/us/healthcare/nasdaq-avco/avalon-globocare

Source 7: https://www.marketwatch.com/press-release/year-end-update-for-this-up-coming-nasdaq-at-the-forefront-of-innovations-in-healthcare-featuring-ai-immunotherapies-avalon-globocare-corp-nasdaqavco-is-avco-the-next-bfri-2022-01-10

Source 8: https://bit.ly/3tZGqcI

Source 9: https://www.proactiveinvestors.com/companies/news/953526/avalon-globocare-says-senlangbio-will-enhance-its-capabilities-in-cell-and-gene-therapy-953526.html

Source 10:https://www.proactiveinvestors.com/companies/news/953526/avalon-globocare-says-senlangbio-will-enhance-its-capabilities-in-cell-and-gene-therapy-953526.html

Source 11: https://www.youtube.com/watch?v=IUlflfiMZT0

Source 12: https://finance.yahoo.com/news/avalon-globocare-announces-study-featuring-130000405.html

Source 13: https://finance.yahoo.com/news/avalon-globocare-expands-ip-portfolio-130000830.html

Source 14:https://njbmagazine.com/monthly-articles/njs-burgeoning-biotech-industry/

Source 15: https://finviz.com/quote.ashx?t=AVCO

Source 16: https://bioinformant.com/product/car-t-funding-brief/

Source 18: https://stockcharts.com/h-sc/ui?s=AVCO

Source 19: https://www.barchart.com/stocks/quotes/AVCO/price-history/historical

Source 20: https://www.tipranks.com/stocks/avco/insider-trading

Source 21: https://schrts.co/qMbaITCq

Source 22: https://www.barchart.com/stocks/quotes/ALBT/price-history/historical?orderBy=tradeTime&orderDir=desc

Source 23: https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=ALBT&insttype=Stock

Source 24: https://www.wallstreetzen.com/how-to-buy-avalon-globocare-stock

Source 25: https://schrts.co/tujpQiHm

Source 26: https://www.marketwatch.com/investing/stock/albt?mod=search_symbol

Source 27: https://www.nasdaq.com/articles/a-small-biotech-stock-for-uncertain-times

Source 28: https://blog.tipranks.com/wp-content/uploads/2022/02/Volatile-stocks-0213-750×406.jpg

Source 29: https://ir.avalon-globocare.com/press-releases/detail/93/avalon-globocare-announces-publication-featuring-qty-code

Source 30: https://ir.avalon-globocare.com/all-sec-filings/content/0001213900-22-023156/ea159234ex99-1_avalonglo.htm

Source 31: https://ir.avalon-globocare.com/press-releases/detail/97/avalon-globocare-announces-nasdaq-ticker-symbol-change-from

Source 32: https://www.citybiz.co/wp-content/uploads/2021/06/Avalon-GloboCare.jpg

Source 33: https://www.wallstreetzen.com/stocks/us/nasdaq/albt/ownership

Source 34: https://www.proactiveinvestors.com/companies/news/997693/avalon-globocare-to-acquire-majority-interest-in-laboratory-services-mso-in-transformative-deal-worth-31m-997693.html

Source 35: https://ir.avalon-globocare.com/press-releases/detail/94/avalon-globocare-receives-allowance-for-joint-u-s-patent

Source 36: https://njbmagazine.com/monthly-articles/njs-burgeoning-biotech-industry/

Source 37: https://d4r15a7jvr7vs.cloudfront.net/ewoJICAgICAgICAgICAgICAgICJidWNrZXQiOiAiZmlsZXMubGJyLmNsb3VkIiwKCSAgICAgICAgICAgICAgICAia2V5IjogInB1YmxpYy8yMDIyLTAxL3VzcHRvIGdyYXBoIHVwIC5qcGciLAoJICAgICAgICAgICAgICAgICJlZGl0cyI6IHsKCSAgICAgICAgICAgICAgICAgICJyZXNpemUiOiB7CgkgICAgICAgICAgICAgICAgICAgICJ3aWR0aCI6IDk0NSwKCSAgICAgICAgICAgICAgICAgICAgImhlaWdodCI6IDUyNiwKCSAgICAgICAgICAgICAgICAgICAgImZpdCI6ICJjb3ZlciIKCSAgICAgICAgICAgICAgICAgIH0KCSAgICAgICAgICAgICAgICB9CgkgICAgICAgICAgICB9

Source 38:https://finance.yahoo.com/news/avalon-globocare-expands-ip-portfolio-130000830.html

Source 39: https://www.cellandgene.com/doc/cell-gene-therapies-investment-outlook-in-beyond-0001

Source 40: https://ir.avalon-globocare.com/press-releases/detail/96/avalon-globocare-signs-definitive-agreement-for